kw1	kw2	inv_edge_weight	pg	iteration	R1C1	edge_weight	crit_p
escherichia coli infections/drug therapy	anti-bacterial agents/adverse effects	0.8301902991225216	0.0	0	1	0.010752688172043	0.0
escherichia coli infections/drug therapy	virus diseases/etiology	0.8301902991225216	0.0	0	1	0.010752688172043	0.0
escherichia coli infections/drug therapy	neoplasms/drug therapy	0.8301902991225216	0.0012043173595439	0	1	0.1290322580645161	0.0026891839170452
escherichia coli infections/drug therapy	clostridium infections/chemically induced	0.8301902991225216	0.0	0	1	0.010752688172043	0.0
anti-bacterial agents/adverse effects	virus diseases/etiology	0.8301902991225216	0.0	0	1	0.010752688172043	0.0
anti-bacterial agents/adverse effects	clostridium infections/chemically induced	0.8301902991225216	0.0	0	1	0.010752688172043	0.0
anti-bacterial agents/adverse effects	neoplasms/drug therapy	0.8301902991225216	0.0012043173595439	0	1	0.1290322580645161	0.0026891839170452
virus diseases/etiology	neoplasms/drug therapy	0.8301902991225216	0.0012043173595439	0	1	0.1290322580645161	0.0026891839170452
virus diseases/etiology	clostridium infections/chemically induced	0.8301902991225216	0.0	0	1	0.010752688172043	0.0
neoplasms/drug therapy	diarrhea/chemically induced	0.0777468263617441	6.952031112539281e-05	0	5	0.0161314791677859	0.0002516978247196
neoplasms/drug therapy	colitis/chemically induced	5.369752206865892e-05	0.0017136073625698	0	11	0.1262339843735465	0.0037111950599129
neoplasms/drug therapy	immune checkpoint inhibitors/adverse effects	5.369752206865892e-05	7.307351886365332e-05	0	11	0.0079594183628137	0.0002635619546159
neoplasms/drug therapy	protein kinase inhibitors/therapeutic use	0.8301902991225216	0.0012043173595439	0	1	0.1290322580645161	0.0026891839170452
neoplasms/drug therapy	glucocorticoids/therapeutic use	0.8301902991225216	0.0046517769353922	0	1	0.1290322580645161	0.008650672897396
neoplasms/drug therapy	tryptophan/pharmacology	0.8301902991225216	0.0001112700446812	0	1	0.1290322580645161	0.0003281348458297
neoplasms/drug therapy	disease progression	0.8301902991225216	0.0046517769353922	0	1	0.1290322580645161	0.008650672897396
neoplasms/drug therapy	chemical and drug induced liver injury/diagnosis	0.8301902991225216	4.861480633611137e-07	0	1	0.1290322580645161	3.0714255128907447e-06
neoplasms/drug therapy	clostridium infections/chemically induced	0.8301902991225216	0.0012043173595439	0	1	0.1290322580645161	0.0026891839170452
neoplasms/drug therapy	abdominal pain/chemically induced	0.8301902991225216	0.0046517769353922	0	1	0.1290322580645161	0.008650672897396
neoplasms/drug therapy	intestinal mucosa/immunology	0.8301902991225216	1.4296142507475018e-05	0	1	0.1290322580645161	5.499403206504503e-05
neoplasms/drug therapy	feces/chemistry	0.8301902991225216	0.0004436759846442	0	1	0.1290322580645161	0.0010715617451913
neoplasms/drug therapy	colon/immunology	0.5846350039324011	1.6323991047784146e-09	0	2	0.0154277699859747	1.2558941499666193e-08
neoplasms/drug therapy	leukocyte l1 antigen complex/analysis	0.8301902991225216	0.0004436759846442	0	1	0.1290322580645161	0.0010715617451913
neoplasms/drug therapy	t-lymphocyte subsets/immunology	0.8301902991225216	1.4296142507475018e-05	0	1	0.1290322580645161	5.499403206504503e-05
neoplasms/drug therapy	gastritis/complications	0.8301902991225216	0.0046517769353922	0	1	0.1290322580645161	0.008650672897396
neoplasms/drug therapy	biological products/therapeutic use	0.8301902991225216	0.0001112700446812	0	1	0.1290322580645161	0.0003281348458297
neoplasms/drug therapy	hepatitis/diagnosis	0.8301902991225216	4.861480633611137e-07	0	1	0.1290322580645161	3.0714255128907447e-06
neoplasms/drug therapy	biomarkers/analysis	0.8301902991225216	0.0004436759846442	0	1	0.1290322580645161	0.0010715617451913
neoplasms/drug therapy	butyrates/metabolism	0.8301902991225216	4.861480633611137e-07	0	1	0.1290322580645161	3.0714255128907447e-06
neoplasms/drug therapy	AHR	0.8301902991225216	0.0001112700446812	0	1	0.1290322580645161	0.0003281348458297
immune system diseases/drug therapy	IL6	0.8301902991225216	0.0017899010765538	0	1	0.021505376344086	0.0037694605453253
immune system diseases/drug therapy	LIF	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
immune system diseases/drug therapy	gastrointestinal neoplasms/drug therapy	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
immune system diseases/drug therapy	BTLA	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
immune system diseases/drug therapy	CD28	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
immune system diseases/drug therapy	CSF2	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
immune system diseases/drug therapy	HAVCR2	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
immune system diseases/drug therapy	IL15	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
immune system diseases/drug therapy	IL17C	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
immune system diseases/drug therapy	IL21	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
immune system diseases/drug therapy	IL22	0.8301902991225216	0.0006439898318757	0	1	0.021505376344086	0.0014984543892913
immune system diseases/drug therapy	IL4	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
IL6	arthritis/chemically induced	0.8301902991225216	1.3102028466271952e-05	0	1	0.021505376344086	5.060459577661313e-05
IL6	glucocorticoids	0.8301902991225216	1.3102028466271952e-05	0	1	0.021505376344086	5.060459577661313e-05
IL6	gastrointestinal neoplasms/drug therapy	0.8301902991225216	0.0017899010765538	0	1	0.021505376344086	0.0037694605453253
IL6	BTLA	0.8301902991225216	0.0017899010765538	0	1	0.021505376344086	0.0037694605453253
IL6	CD28	0.8301902991225216	0.0017899010765538	0	1	0.021505376344086	0.0037694605453253
IL6	CHI3L1	0.8301902991225216	1.3102028466271952e-05	0	1	0.021505376344086	5.060459577661313e-05
IL6	CSF2	0.8301902991225216	0.0017899010765538	0	1	0.021505376344086	0.0037694605453253
IL6	CXCL8	0.8301902991225216	1.3102028466271952e-05	0	1	0.021505376344086	5.060459577661313e-05
IL6	HAVCR2	0.8301902991225216	0.0017899010765538	0	1	0.021505376344086	0.0037694605453253
IL6	IL15	0.8301902991225216	0.0017899010765538	0	1	0.021505376344086	0.0037694605453253
IL6	IL17C	0.8301902991225216	0.0017899010765538	0	1	0.021505376344086	0.0037694605453253
IL6	IL21	0.8301902991225216	0.0017899010765538	0	1	0.021505376344086	0.0037694605453253
IL6	IL4	0.8301902991225216	0.0017899010765538	0	1	0.021505376344086	0.0037694605453253
IL6	LIF	0.8301902991225216	0.0017899010765538	0	1	0.021505376344086	0.0037694605453253
LIF	gastrointestinal neoplasms/drug therapy	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
LIF	BTLA	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
LIF	CD28	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
LIF	CSF2	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
LIF	HAVCR2	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
LIF	IL15	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
LIF	IL17C	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
LIF	IL21	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
LIF	IL22	0.8301902991225216	0.0006439898318757	0	1	0.021505376344086	0.0014984543892913
LIF	IL4	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
gastrointestinal neoplasms/drug therapy	BTLA	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
gastrointestinal neoplasms/drug therapy	CD28	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
gastrointestinal neoplasms/drug therapy	CSF2	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
gastrointestinal neoplasms/drug therapy	HAVCR2	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
gastrointestinal neoplasms/drug therapy	IL15	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
gastrointestinal neoplasms/drug therapy	IL17C	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
gastrointestinal neoplasms/drug therapy	IL21	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
gastrointestinal neoplasms/drug therapy	IL22	0.8301902991225216	0.0006439898318757	0	1	0.021505376344086	0.0014984543892913
gastrointestinal neoplasms/drug therapy	IL4	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
BTLA	CD28	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
BTLA	CSF2	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
BTLA	HAVCR2	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
BTLA	IL15	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
BTLA	IL17C	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
BTLA	IL21	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
BTLA	IL22	0.8301902991225216	0.0006439898318757	0	1	0.021505376344086	0.0014984543892913
BTLA	IL4	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
CD28	CSF2	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
CD28	HAVCR2	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
CD28	IL15	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
CD28	IL17C	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
CD28	IL21	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
CD28	IL22	0.8301902991225216	0.0006439898318757	0	1	0.021505376344086	0.0014984543892913
CD28	IL4	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
CSF2	HAVCR2	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
CSF2	IL15	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
CSF2	IL17C	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
CSF2	IL21	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
CSF2	IL22	0.8301902991225216	0.0006439898318757	0	1	0.021505376344086	0.0014984543892913
CSF2	IL4	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
HAVCR2	IL15	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
HAVCR2	IL17C	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
HAVCR2	IL21	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
HAVCR2	IL22	0.8301902991225216	0.0006439898318757	0	1	0.021505376344086	0.0014984543892913
HAVCR2	IL4	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
IL15	IL17C	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
IL15	IL21	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
IL15	IL22	0.8301902991225216	0.0006439898318757	0	1	0.021505376344086	0.0014984543892913
IL15	IL4	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
IL17C	IL21	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
IL17C	IL22	0.8301902991225216	0.0006439898318757	0	1	0.021505376344086	0.0014984543892913
IL17C	IL4	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
IL21	IL22	0.8301902991225216	0.0006439898318757	0	1	0.021505376344086	0.0014984543892913
IL21	IL4	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
IL22	tryptophan/pharmacology	0.8301902991225216	1.4288104033255422e-10	0	1	0.021505376344086	1.4978957415083155e-09
IL22	immune checkpoint inhibitors/pharmacology	0.8301902991225216	0.0045271389450379	0	1	0.0846189808321645	0.0084684128501298
IL22	AHR	0.8301902991225216	1.4288104033255422e-10	0	1	0.021505376344086	1.4978957415083155e-09
IL22	IL4	0.8301902991225216	0.0006439898318757	0	1	0.021505376344086	0.0014984543892913
arthritis/chemically induced	nivolumab/therapeutic use	0.8301902991225216	1.9186614984678663e-05	0	1	0.021505376344086	7.234794741258278e-05
arthritis/chemically induced	IL17A	0.8301902991225216	1.3102028466271952e-05	0	1	0.021505376344086	5.060459577661313e-05
arthritis/chemically induced	glucocorticoids	0.8301902991225216	6.983302824892236e-14	0	1	0.010752688172043	1.1196757806633936e-12
arthritis/chemically induced	CHI3L1	0.8301902991225216	6.983302824892236e-14	0	1	0.010752688172043	1.1196757806633936e-12
arthritis/chemically induced	CXCL8	0.8301902991225216	6.983302824892236e-14	0	1	0.010752688172043	1.1196757806633936e-12
glucocorticoids	nivolumab/therapeutic use	0.8301902991225216	1.9186614984678663e-05	0	1	0.021505376344086	7.234794741258278e-05
glucocorticoids	IL17A	0.8301902991225216	1.3102028466271952e-05	0	1	0.021505376344086	5.060459577661313e-05
glucocorticoids	CHI3L1	0.8301902991225216	6.983302824892236e-14	0	1	0.010752688172043	1.1196757806633936e-12
glucocorticoids	CXCL8	0.8301902991225216	6.983302824892236e-14	0	1	0.010752688172043	1.1196757806633936e-12
CHI3L1	nivolumab/therapeutic use	0.8301902991225216	1.9186614984678663e-05	0	1	0.021505376344086	7.234794741258278e-05
CHI3L1	IL17A	0.8301902991225216	1.3102028466271952e-05	0	1	0.021505376344086	5.060459577661313e-05
CHI3L1	CXCL8	0.8301902991225216	6.983302824892236e-14	0	1	0.010752688172043	1.1196757806633936e-12
CXCL8	nivolumab/therapeutic use	0.8301902991225216	1.9186614984678663e-05	0	1	0.021505376344086	7.234794741258278e-05
CXCL8	IL17A	0.8301902991225216	1.3102028466271952e-05	0	1	0.021505376344086	5.060459577661313e-05
protective agents/pharmacology	mesalamine/pharmacology	0.8301902991225216	0.0	0	1	0.010752688172043	0.0
protective agents/pharmacology	colon/drug effects	0.8301902991225216	2.3439723022211645e-05	0	1	0.032258064516129	8.717932071419068e-05
protective agents/pharmacology	immune checkpoint inhibitors/pharmacology	0.8301902991225216	1.3929446125438003e-06	0	1	0.043010752688172	8.228292014655019e-06
protective agents/pharmacology	trinitrobenzenesulfonic acid/adverse effects	0.8301902991225216	0.0	0	1	0.010752688172043	0.0
protective agents/pharmacology	ACAD8	0.8301902991225216	2.896401563035056e-09	0	1	0.021505376344086	2.1419899931282507e-08
mesalamine/pharmacology	colon/drug effects	0.8301902991225216	2.3439723022211645e-05	0	1	0.032258064516129	8.717932071419068e-05
mesalamine/pharmacology	ACAD8	0.8301902991225216	2.896401563035056e-09	0	1	0.021505376344086	2.1419899931282507e-08
mesalamine/pharmacology	immune checkpoint inhibitors/pharmacology	0.8301902991225216	1.3929446125438003e-06	0	1	0.043010752688172	8.228292014655019e-06
mesalamine/pharmacology	trinitrobenzenesulfonic acid/adverse effects	0.8301902991225216	0.0	0	1	0.010752688172043	0.0
colon/drug effects	colitis ulcerative/immunology	0.5846350039324011	1.4228516045378117e-06	0	2	0.0007012622720897	8.302143307211451e-06
colon/drug effects	macrophages/drug effects	0.8301902991225216	0.0001660054582111	0	1	0.032258064516129	0.0004664777824253
colon/drug effects	interferon-gamma/metabolism	0.8301902991225216	0.0010372325214909	0	1	0.032258064516129	0.0023588076889209
colon/drug effects	immunologic memory/drug effects	0.8301902991225216	0.0010372325214909	0	1	0.032258064516129	0.0023588076889209
colon/drug effects	crohn disease/immunology	0.8301902991225216	0.0001660054582111	0	1	0.032258064516129	0.0004664777824253
colon/drug effects	trinitrobenzenesulfonic acid/adverse effects	0.8301902991225216	2.3439723022211645e-05	0	1	0.032258064516129	8.717932071419068e-05
colon/drug effects	graft vs host disease/immunology	0.8301902991225216	0.0001660054582111	0	1	0.032258064516129	0.0004664777824253
colon/drug effects	cd8-positive t-lymphocytes/drug effects	0.5846350039324011	1.4228516045378117e-06	0	2	0.0007012622720897	8.302143307211451e-06
colon/drug effects	phenotype	0.5846350039324011	1.4228516045378117e-06	0	2	0.0007012622720897	8.302143307211451e-06
colon/drug effects	ACAD8	0.8301902991225216	0.0033230272463853	0	1	0.0638148667601683	0.0063786076318945
immune checkpoint inhibitors/pharmacology	inflammatory bowel diseases	0.8301902991225216	9.105000230447136e-05	0	1	0.0846189808321645	0.0002777578837603
immune checkpoint inhibitors/pharmacology	colitis/diagnosis	0.8301902991225216	4.232276377758026e-05	0	1	0.0846189808321645	0.0001541065520756
immune checkpoint inhibitors/pharmacology	ACAD8	0.8301902991225216	0.0007650097159677	0	1	0.0846189808321645	0.001771405992799
immune checkpoint inhibitors/pharmacology	colitis collagenous/drug therapy	0.8301902991225216	6.3687943807622105e-12	0	1	0.043010752688172	9.068402745144997e-11
immune checkpoint inhibitors/pharmacology	skin neoplasms/complications	0.8301902991225216	6.3687943807622105e-12	0	1	0.043010752688172	9.068402745144997e-11
immune checkpoint inhibitors/pharmacology	tryptophan/pharmacology	0.8301902991225216	8.488771907622095e-10	0	1	0.043010752688172	7.743202371973273e-09
immune checkpoint inhibitors/pharmacology	programmed cell death 1 receptor/metabolism	0.8301902991225216	2.365995095399143e-07	0	1	0.043010752688172	1.5354825312998518e-06
immune checkpoint inhibitors/pharmacology	trinitrobenzenesulfonic acid/adverse effects	0.8301902991225216	1.3929446125438003e-06	0	1	0.043010752688172	8.228292014655019e-06
immune checkpoint inhibitors/pharmacology	gastrointestinal tract/metabolism	0.8301902991225216	2.365995095399143e-07	0	1	0.043010752688172	1.5354825312998518e-06
immune checkpoint inhibitors/pharmacology	b7-h1 antigen/metabolism	0.8301902991225216	2.365995095399143e-07	0	1	0.043010752688172	1.5354825312998518e-06
immune checkpoint inhibitors/pharmacology	AHR	0.8301902991225216	8.488771907622095e-10	0	1	0.043010752688172	7.743202371973273e-09
trinitrobenzenesulfonic acid/adverse effects	ACAD8	0.8301902991225216	2.896401563035056e-09	0	1	0.021505376344086	2.1419899931282507e-08
ACAD8	urothelium/drug effects	0.8301902991225216	2.896401563035056e-09	0	1	0.021505376344086	2.1419899931282507e-08
ACAD8	carcinoma non-small-cell lung/complications	0.8301902991225216	2.896401563035056e-09	0	1	0.021505376344086	2.1419899931282507e-08
ACAD8	drug-related side effects and adverse reactions	0.8301902991225216	3.632071685855109e-06	0	1	0.0427769985974754	2.0748481367100445e-05
ACAD8	melanoma/complications	0.8301902991225216	0.0005782582526319	0	1	0.0638148667601683	0.0013705798087225
ACAD8	infliximab/administration & dosage	0.8301902991225216	2.896401563035056e-09	0	1	0.021505376344086	2.1419899931282507e-08
ACAD8	CRP	0.8301902991225216	2.896401563035056e-09	0	1	0.021505376344086	2.1419899931282507e-08
PDCD1	CD274	2.381978550337223e-06	0.0005382898811121	0	13	1.555727321934218e-07	0.0012774341954751
PDCD1	CTLA4	5.369752206865892e-05	0.001293939617514	0	11	7.400826146728449e-07	0.0028224172203267
CD274	b7-h1 antigen/antagonists & inhibitors	0.3479096080556238	0.0002239297954592	0	3	0.0035063113604488	0.0005814517869145
CD274	CTLA4	0.010308700389748	0.0020080863838891	0	7	0.0003490778454898	0.0040587169708268
CTLA4	colitis	0.5846350039324011	0.0045640144008352	0	2	0.0795123530046391	0.0085206844195631
CTLA4	inflammatory bowel diseases/drug therapy	0.5846350039324011	0.0045640144008352	0	2	0.042892591279688	0.0085206844195631
CTLA4	ctla-4 antigen/antagonists & inhibitors	0.3479096080556238	0.0025224336864024	0	3	0.0016953593391181	0.0050448673728049
neoplasms	immune checkpoint inhibitors	0.5846350039324011	0.0025310276064748	0	2	0.3879598662207357	0.0050567546315748
neoplasms	infliximab/adverse effects	0.8301902991225216	0.0003058560984983	0	1	0.1637508198518016	0.0007520276236272
neoplasms	colitis	0.8301902991225216	2.7358273814281908e-05	0	1	0.1637508198518016	0.0001015556156374
neoplasms	recurrence	0.8301902991225216	7.771561172376097e-16	0	1	0.043010752688172	1.6660830018981562e-14
neoplasms	diarrhea	0.8301902991225216	1.0481615575486105e-11	0	1	0.0846189808321645	1.481401668002036e-10
neoplasms	inflammatory bowel diseases	0.8301902991225216	2.365995095399143e-07	0	1	0.0846189808321645	1.5354825312998518e-06
neoplasms	LTF	0.8301902991225216	7.771561172376097e-16	0	1	0.043010752688172	1.6660830018981562e-14
immune checkpoint inhibitors	colitis ulcerative	0.8301902991225216	3.0242941484459607e-10	0	1	0.3225806451612903	3.119109856883726e-09
immune checkpoint inhibitors	colitis/therapy	0.8301902991225216	9.99540715695968e-06	0	1	0.3225806451612903	4.049094873774749e-05
immune checkpoint inhibitors	diarrhea	0.5846350039324011	5.909337781773161e-06	0	2	0.1016830294530154	3.3556596689354734e-05
immune checkpoint inhibitors	prednisolone/therapeutic use	0.8301902991225216	0.0021298880586121	0	1	0.3225806451612903	0.0043003454135787
immune checkpoint inhibitors	carcinoma non-small-cell lung	0.8301902991225216	0.0003476938855124	0	1	0.3225806451612903	0.0008472540658465
immune checkpoint inhibitors	esophagitis	0.8301902991225216	0.0003476938855124	0	1	0.3225806451612903	0.0008472540658465
immune checkpoint inhibitors	ulcer/chemically induced	0.8301902991225216	0.0003476938855124	0	1	0.3225806451612903	0.0008472540658465
immune checkpoint inhibitors	diarrhea/therapy	0.8301902991225216	0.0003476938855124	0	1	0.3225806451612903	0.0008472540658465
immune checkpoint inhibitors	colitis	0.3479096080556238	6.683084623093638e-05	0	3	0.0969899665551839	0.000242420636138
immune checkpoint inhibitors	colitis microscopic/chemically induced	0.5846350039324011	8.11341549500355e-10	0	2	0.1016830294530154	7.743202371973273e-09
immune checkpoint inhibitors	immunologic factors	0.5846350039324011	8.11341549500355e-10	0	2	0.1016830294530154	7.743202371973273e-09
immune checkpoint inhibitors	neoplasms/therapy	0.8301902991225216	0.0003476938855124	0	1	0.3225806451612903	0.0008472540658465
immune checkpoint inhibitors	colitis/chemically induced	8.370089365957815e-13	3.344098559976416e-05	0	21	0.8143583149525486	0.0001229391146904
immune checkpoint inhibitors	crohn disease/drug therapy	0.8301902991225216	9.99540715695968e-06	0	1	0.3225806451612903	4.049094873774749e-05
immune checkpoint inhibitors	lung neoplasms	0.8301902991225216	0.0003476938855124	0	1	0.3225806451612903	0.0008472540658465
immune checkpoint inhibitors	cd8-positive t-lymphocytes	0.8301902991225216	0.0003476938855124	0	1	0.3225806451612903	0.0008472540658465
immune checkpoint inhibitors	cytomegalovirus infections/complications	0.8301902991225216	9.99540715695968e-06	0	1	0.3225806451612903	4.049094873774749e-05
immune checkpoint inhibitors	TNF	0.3479096080556238	0.0006526577599305	0	3	0.0312870859855432	0.0015167734542599
infliximab/adverse effects	intestinal mucosa/diagnostic imaging	0.8301902991225216	1.694835870669209e-05	0	1	0.043010752688172	6.441726775372214e-05
infliximab/adverse effects	drug resistance/immunology	0.8301902991225216	1.694835870669209e-05	0	1	0.043010752688172	6.441726775372214e-05
infliximab/adverse effects	colon/diagnostic imaging	0.8301902991225216	1.694835870669209e-05	0	1	0.043010752688172	6.441726775372214e-05
infliximab/adverse effects	skin neoplasms/drug therapy	0.8301902991225216	0.0015703678212359	0	1	0.0846189808321645	0.0034087164993381
infliximab/adverse effects	antibodies monoclonal humanized/therapeutic use	0.8301902991225216	6.3687943807622105e-12	0	1	0.043010752688172	9.068402745144997e-11
infliximab/adverse effects	steroids/adverse effects	0.8301902991225216	6.3687943807622105e-12	0	1	0.043010752688172	9.068402745144997e-11
infliximab/adverse effects	glucocorticoids/pharmacology	0.8301902991225216	1.694835870669209e-05	0	1	0.043010752688172	6.441726775372214e-05
infliximab/adverse effects	melanoma/drug therapy	0.5846350039324011	2.481876979598674e-06	0	2	0.0134138885892041	1.4220484315538348e-05
infliximab/adverse effects	immunosuppressive agents/pharmacology	0.8301902991225216	1.694835870669209e-05	0	1	0.043010752688172	6.441726775372214e-05
infliximab/adverse effects	drug-related side effects and adverse reactions	0.8301902991225216	0.0001746066731989	0	1	0.0846189808321645	0.0004899257830345
infliximab/adverse effects	mucositis/chemically induced	0.8301902991225216	1.694835870669209e-05	0	1	0.043010752688172	6.441726775372214e-05
infliximab/adverse effects	LTF	0.8301902991225216	8.488771907622095e-10	0	1	0.043010752688172	7.743202371973273e-09
colitis	diarrhea	0.5846350039324011	0.0	0	2	0.0014025245441795	0.0
colitis	pneumonia	0.8301902991225216	9.620737539961509e-11	0	1	0.043010752688172	1.0197981792359201e-09
colitis	inflammatory bowel diseases/drug therapy	0.8301902991225216	0.0002334339983105	0	1	0.1248555091472342	0.0005814517869145
colitis	recurrence	0.8301902991225216	1.2526646386845641e-12	0	1	0.043010752688172	1.8672532270391784e-11
colitis	inflammatory bowel diseases	0.8301902991225216	5.566439962856329e-06	0	1	0.0846189808321645	3.170378343023843e-05
colitis	ligands	0.8301902991225216	9.620737539961509e-11	0	1	0.043010752688172	1.0197981792359201e-09
recurrence	diarrhea	0.8301902991225216	0.0	0	1	0.021505376344086	0.0
recurrence	inflammatory bowel diseases	0.8301902991225216	0.0	0	1	0.021505376344086	0.0
diarrhea	inflammatory bowel diseases	0.8301902991225216	1.957323192414151e-13	0	1	0.0427769985974754	3.0117521380050002e-12
inflammatory bowel diseases	colitis/diagnosis	0.8301902991225216	5.063311991904129e-09	0	1	0.0427769985974754	3.715692030981953e-08
inflammatory bowel diseases	programmed cell death 1 receptor/metabolism	0.8301902991225216	1.957323192414151e-13	0	1	0.021505376344086	3.0117521380050002e-12
inflammatory bowel diseases	gastrointestinal tract/metabolism	0.8301902991225216	1.957323192414151e-13	0	1	0.021505376344086	3.0117521380050002e-12
inflammatory bowel diseases	b7-h1 antigen/metabolism	0.8301902991225216	1.957323192414151e-13	0	1	0.021505376344086	3.0117521380050002e-12
LTF	diarrhea/chemically induced	0.8301902991225216	0.001239801514261	0	1	0.1505376344086021	0.0027158912620093
colitis/therapy	immunologic factors	0.8301902991225216	0.0	0	1	0.021505376344086	0.0
prednisolone/therapeutic use	nivolumab/adverse effects	0.8301902991225216	8.279835420732518e-06	0	1	0.1290322580645161	3.540508179502065e-05
prednisolone/therapeutic use	lung neoplasms/drug therapy	0.8301902991225216	0.0	0	1	0.021505376344086	0.0
carcinoma non-small-cell lung	cd8-positive t-lymphocytes	0.8301902991225216	0.0	0	1	0.010752688172043	0.0
esophagitis	ulcer/chemically induced	0.8301902991225216	0.0	0	1	0.010752688172043	0.0
diarrhea/therapy	colitis/drug therapy	0.8301902991225216	1.887379141862766e-15	0	1	0.032258064516129	3.957274068872701e-14
diarrhea/therapy	neoplasms/therapy	0.8301902991225216	0.0	0	1	0.010752688172043	0.0
colitis microscopic/chemically induced	inflammatory bowel diseases/complications	0.8301902991225216	0.0	0	1	0.0427769985974754	0.0
neoplasms/therapy	colitis/drug therapy	0.8301902991225216	1.887379141862766e-15	0	1	0.032258064516129	3.957274068872701e-14
colitis/chemically induced	nivolumab/adverse effects	0.0002278681042509	0.0041246524905659	0	10	0.3515184224404146	0.0077230980883216
colitis/chemically induced	immune checkpoint inhibitors/adverse effects	0.0	6.640305417915382e-05	0	41	0.28552761772611	0.0002413276711882
colitis/chemically induced	ipilimumab/adverse effects	0.0008903144156418	0.0007075612536729	0	9	0.0589207356081562	0.0016423684574307
crohn disease/drug therapy	colitis ulcerative/drug therapy	0.8301902991225216	0.0	0	1	0.021505376344086	0.0
lung neoplasms	steroids/therapeutic use	0.8301902991225216	0.0	0	1	0.021505376344086	0.0
TNF	adrenal cortex hormones/therapeutic use	0.8301902991225216	0.0012219719371479	0	1	0.0946781129109319	0.0026891839170452
TNF	SNCA	0.8301902991225216	0.0036748977609006	0	1	0.0946781129109319	0.0068877258622775
TNF	psoriasis	0.8301902991225216	1.095585194110793e-05	0	1	0.032258064516129	4.301186317620151e-05
TNF	tumor necrosis factor inhibitors	0.8301902991225216	8.113733580561444e-07	0	1	0.032258064516129	4.852979207432989e-06
TNF	skin neoplasms/drug therapy	0.8301902991225216	0.0012219719371479	0	1	0.0638148667601683	0.0026891839170452
TNF	dermatitis	0.8301902991225216	1.095585194110793e-05	0	1	0.032258064516129	4.301186317620151e-05
TNF	melanoma/drug therapy	0.5846350039324011	1.4228516045378117e-06	0	2	0.0068584991446141	8.302143307211451e-06
TNF	rna	0.8301902991225216	1.095585194110793e-05	0	1	0.032258064516129	4.301186317620151e-05
TNF	drug-related side effects and adverse reactions	0.8301902991225216	0.000124270133592	0	1	0.0638148667601683	0.0003619960532727
TNF	CXCL10	0.8301902991225216	1.095585194110793e-05	0	1	0.032258064516129	4.301186317620151e-05
TNF	CXCL9	0.8301902991225216	1.095585194110793e-05	0	1	0.032258064516129	4.301186317620151e-05
TNF	TCIM	0.8301902991225216	1.095585194110793e-05	0	1	0.032258064516129	4.301186317620151e-05
intestinal mucosa/diagnostic imaging	colon/diagnostic imaging	0.8301902991225216	1.6913137557139635e-11	0	1	0.010752688172043	1.9094832224273623e-10
intestinal mucosa/diagnostic imaging	drug resistance/immunology	0.8301902991225216	1.6913137557139635e-11	0	1	0.010752688172043	1.9094832224273623e-10
intestinal mucosa/diagnostic imaging	skin neoplasms/drug therapy	0.8301902991225216	6.083958906666354e-07	0	1	0.021505376344086	3.696876940738663e-06
intestinal mucosa/diagnostic imaging	glucocorticoids/pharmacology	0.8301902991225216	1.6913137557139635e-11	0	1	0.010752688172043	1.9094832224273623e-10
intestinal mucosa/diagnostic imaging	melanoma/drug therapy	0.8301902991225216	0.0001660054582111	0	1	0.053763440860215	0.0004664777824253
intestinal mucosa/diagnostic imaging	immunosuppressive agents/pharmacology	0.8301902991225216	1.6913137557139635e-11	0	1	0.010752688172043	1.9094832224273623e-10
intestinal mucosa/diagnostic imaging	mucositis/chemically induced	0.8301902991225216	1.6913137557139635e-11	0	1	0.010752688172043	1.9094832224273623e-10
drug resistance/immunology	colon/diagnostic imaging	0.8301902991225216	1.6913137557139635e-11	0	1	0.010752688172043	1.9094832224273623e-10
drug resistance/immunology	skin neoplasms/drug therapy	0.8301902991225216	6.083958906666354e-07	0	1	0.021505376344086	3.696876940738663e-06
drug resistance/immunology	glucocorticoids/pharmacology	0.8301902991225216	1.6913137557139635e-11	0	1	0.010752688172043	1.9094832224273623e-10
drug resistance/immunology	melanoma/drug therapy	0.8301902991225216	0.0001660054582111	0	1	0.053763440860215	0.0004664777824253
drug resistance/immunology	immunosuppressive agents/pharmacology	0.8301902991225216	1.6913137557139635e-11	0	1	0.010752688172043	1.9094832224273623e-10
drug resistance/immunology	mucositis/chemically induced	0.8301902991225216	1.6913137557139635e-11	0	1	0.010752688172043	1.9094832224273623e-10
colon/diagnostic imaging	immunosuppressive agents/pharmacology	0.8301902991225216	1.6913137557139635e-11	0	1	0.010752688172043	1.9094832224273623e-10
colon/diagnostic imaging	mucositis/chemically induced	0.8301902991225216	1.6913137557139635e-11	0	1	0.010752688172043	1.9094832224273623e-10
colon/diagnostic imaging	skin neoplasms/drug therapy	0.8301902991225216	6.083958906666354e-07	0	1	0.021505376344086	3.696876940738663e-06
colon/diagnostic imaging	glucocorticoids/pharmacology	0.8301902991225216	1.6913137557139635e-11	0	1	0.010752688172043	1.9094832224273623e-10
colon/diagnostic imaging	melanoma/drug therapy	0.8301902991225216	0.0001660054582111	0	1	0.053763440860215	0.0004664777824253
skin neoplasms/drug therapy	adrenal cortex hormones/therapeutic use	0.8301902991225216	0.0002334339983105	0	1	0.0638148667601683	0.0005814517869145
skin neoplasms/drug therapy	SNCA	0.8301902991225216	0.0009302340538402	0	1	0.0638148667601683	0.0021230700654632
skin neoplasms/drug therapy	tumor necrosis factor inhibitors	0.8301902991225216	2.2507388619530392e-08	0	1	0.021505376344086	1.5068104381075084e-07
skin neoplasms/drug therapy	glucocorticoids/pharmacology	0.8301902991225216	6.083958906666354e-07	0	1	0.021505376344086	3.696876940738663e-06
skin neoplasms/drug therapy	melanoma/drug therapy	0.5846350039324011	3.5446682589146405e-08	0	2	0.0023375409069658	2.3647646986045925e-07
skin neoplasms/drug therapy	immunosuppressive agents/pharmacology	0.8301902991225216	6.083958906666354e-07	0	1	0.021505376344086	3.696876940738663e-06
skin neoplasms/drug therapy	mucositis/chemically induced	0.8301902991225216	6.083958906666354e-07	0	1	0.021505376344086	3.696876940738663e-06
antibodies monoclonal humanized/therapeutic use	steroids/adverse effects	0.8301902991225216	0.0	0	1	0.010752688172043	0.0
glucocorticoids/pharmacology	melanoma/drug therapy	0.8301902991225216	0.0001660054582111	0	1	0.053763440860215	0.0004664777824253
glucocorticoids/pharmacology	immunosuppressive agents/pharmacology	0.8301902991225216	1.6913137557139635e-11	0	1	0.010752688172043	1.9094832224273623e-10
glucocorticoids/pharmacology	mucositis/chemically induced	0.8301902991225216	1.6913137557139635e-11	0	1	0.010752688172043	1.9094832224273623e-10
melanoma/drug therapy	vitamin d	0.8301902991225216	1.5989729540422102e-09	0	1	0.053763440860215	1.2351580551872621e-08
melanoma/drug therapy	tumor necrosis factor inhibitors	0.8301902991225216	2.3439723022211645e-05	0	1	0.053763440860215	8.717932071419068e-05
melanoma/drug therapy	immunosuppressive agents/pharmacology	0.8301902991225216	0.0001660054582111	0	1	0.053763440860215	0.0004664777824253
melanoma/drug therapy	drug-related side effects and adverse reactions	0.8301902991225216	0.0010372325214909	0	1	0.1051893408134642	0.0023588076889209
melanoma/drug therapy	mucositis/chemically induced	0.8301902991225216	0.0001660054582111	0	1	0.053763440860215	0.0004664777824253
immunosuppressive agents/pharmacology	mucositis/chemically induced	0.8301902991225216	1.6913137557139635e-11	0	1	0.010752688172043	1.9094832224273623e-10
drug-related side effects and adverse reactions	urothelium/drug effects	0.8301902991225216	4.169464773440268e-11	0	1	0.021505376344086	4.598461727008111e-10
drug-related side effects and adverse reactions	carcinoma non-small-cell lung/complications	0.8301902991225216	4.169464773440268e-11	0	1	0.021505376344086	4.598461727008111e-10
drug-related side effects and adverse reactions	melanoma/complications	0.8301902991225216	0.000124270133592	0	1	0.0638148667601683	0.0003619960532727
drug-related side effects and adverse reactions	infliximab/administration & dosage	0.8301902991225216	4.169464773440268e-11	0	1	0.021505376344086	4.598461727008111e-10
drug-related side effects and adverse reactions	CRP	0.8301902991225216	4.169464773440268e-11	0	1	0.021505376344086	4.598461727008111e-10
adrenal cortex hormones/therapeutic use	SNCA	0.8301902991225216	0.0009302340538402	0	1	0.0946781129109319	0.0021230700654632
adrenal cortex hormones/therapeutic use	inflammation/drug therapy	0.8301902991225216	0.0004982368131516	0	1	0.0638148667601683	0.0011838553418347
adrenal cortex hormones/therapeutic use	tumor necrosis factor inhibitors	0.8301902991225216	2.2507388619530392e-08	0	1	0.032258064516129	1.5068104381075084e-07
adrenal cortex hormones/therapeutic use	diarrhea/chemically induced	0.3479096080556238	1.3700446152009604e-06	0	3	0.002805049088359	8.168891018135727e-06
adrenal cortex hormones/therapeutic use	biological products/therapeutic use	0.8301902991225216	1.2526646386845641e-12	0	1	0.032258064516129	1.8672532270391784e-11
adrenal cortex hormones/therapeutic use	beclomethasone/adverse effects	0.8301902991225216	1.2526646386845641e-12	0	1	0.032258064516129	1.8672532270391784e-11
SNCA	hashimoto disease/chemically induced	0.8301902991225216	2.031169205829464e-06	0	1	0.032258064516129	1.1673104953983784e-05
SNCA	squamous cell carcinoma of head and neck/drug therapy	0.8301902991225216	2.031169205829464e-06	0	1	0.032258064516129	1.1673104953983784e-05
SNCA	tongue neoplasms/drug therapy	0.8301902991225216	2.031169205829464e-06	0	1	0.032258064516129	1.1673104953983784e-05
SNCA	tumor necrosis factor inhibitors	0.8301902991225216	4.503715761439153e-07	0	1	0.032258064516129	2.8739430343899343e-06
SNCA	paclitaxel/therapeutic use	0.8301902991225216	2.031169205829464e-06	0	1	0.032258064516129	1.1673104953983784e-05
SNCA	colitis ulcerative/chemically induced	0.8301902991225216	2.031169205829464e-06	0	1	0.032258064516129	1.1673104953983784e-05
inflammation/drug therapy	melanoma/genetics	0.8301902991225216	0.0001276936833728	0	1	0.021505376344086	0.00036582514696
inflammation/drug therapy	receptors cxcr6/genetics	0.8301902991225216	0.0001276936833728	0	1	0.021505376344086	0.00036582514696
inflammation/drug therapy	gene expression regulation/genetics	0.8301902991225216	0.0001276936833728	0	1	0.021505376344086	0.00036582514696
inflammation/drug therapy	receptors cxcr3/genetics	0.8301902991225216	0.0001276936833728	0	1	0.021505376344086	0.00036582514696
inflammation/drug therapy	cd8-positive t-lymphocytes/cytology	0.8301902991225216	0.0001276936833728	0	1	0.021505376344086	0.00036582514696
inflammation/drug therapy	myeloid cells/cytology	0.8301902991225216	0.0001276936833728	0	1	0.021505376344086	0.00036582514696
inflammation/drug therapy	ctla-4 antigen/immunology	0.8301902991225216	0.0001276936833728	0	1	0.021505376344086	0.00036582514696
inflammation/drug therapy	colitis/drug therapy	0.8301902991225216	0.0028052417422615	0	1	0.0638148667601683	0.005535058163635
inflammation/drug therapy	receptors antigen t-cell/genetics	0.8301902991225216	0.0001276936833728	0	1	0.021505376344086	0.00036582514696
inflammation/drug therapy	t-lymphocytes regulatory/cytology	0.8301902991225216	0.0001276936833728	0	1	0.021505376344086	0.00036582514696
inflammation/drug therapy	chemokines/metabolism	0.8301902991225216	0.0001276936833728	0	1	0.021505376344086	0.00036582514696
inflammation/drug therapy	multigene family	0.8301902991225216	0.0001276936833728	0	1	0.021505376344086	0.00036582514696
inflammation/drug therapy	beclomethasone/adverse effects	0.8301902991225216	1.6913137557139635e-11	0	1	0.021505376344086	1.9094832224273623e-10
diarrhea/chemically induced	feces	0.8301902991225216	0.001239801514261	0	1	0.1505376344086021	0.0027158912620093
diarrhea/chemically induced	feces/chemistry	0.8301902991225216	0.0033916470872356	0	1	0.1505376344086021	0.0064907348469864
diarrhea/chemically induced	leukocyte l1 antigen complex/analysis	0.8301902991225216	0.0033916470872356	0	1	0.1505376344086021	0.0064907348469864
diarrhea/chemically induced	biological products/therapeutic use	0.8301902991225216	0.001239801514261	0	1	0.1505376344086021	0.0027158912620093
diarrhea/chemically induced	beclomethasone/adverse effects	0.8301902991225216	0.001239801514261	0	1	0.1505376344086021	0.0027158912620093
diarrhea/chemically induced	biomarkers/analysis	0.8301902991225216	0.0033916470872356	0	1	0.1505376344086021	0.0064907348469864
hashimoto disease/chemically induced	nivolumab/adverse effects	0.8301902991225216	0.0036027646835737	0	1	0.1290322580645161	0.0067591691408641
hashimoto disease/chemically induced	squamous cell carcinoma of head and neck/drug therapy	0.8301902991225216	6.983302824892236e-14	0	1	0.010752688172043	1.1196757806633936e-12
hashimoto disease/chemically induced	tongue neoplasms/drug therapy	0.8301902991225216	6.983302824892236e-14	0	1	0.010752688172043	1.1196757806633936e-12
hashimoto disease/chemically induced	paclitaxel/therapeutic use	0.8301902991225216	6.983302824892236e-14	0	1	0.010752688172043	1.1196757806633936e-12
hashimoto disease/chemically induced	colitis ulcerative/chemically induced	0.8301902991225216	6.983302824892236e-14	0	1	0.010752688172043	1.1196757806633936e-12
hashimoto disease/chemically induced	antineoplastic agents immunological/adverse effects	0.8301902991225216	0.0009302340538402	0	1	0.075268817204301	0.0021230700654632
squamous cell carcinoma of head and neck/drug therapy	nivolumab/adverse effects	0.8301902991225216	0.0036027646835737	0	1	0.1290322580645161	0.0067591691408641
squamous cell carcinoma of head and neck/drug therapy	paclitaxel/therapeutic use	0.8301902991225216	6.983302824892236e-14	0	1	0.010752688172043	1.1196757806633936e-12
squamous cell carcinoma of head and neck/drug therapy	colitis ulcerative/chemically induced	0.8301902991225216	6.983302824892236e-14	0	1	0.010752688172043	1.1196757806633936e-12
squamous cell carcinoma of head and neck/drug therapy	antineoplastic agents immunological/adverse effects	0.8301902991225216	0.0009302340538402	0	1	0.075268817204301	0.0021230700654632
squamous cell carcinoma of head and neck/drug therapy	tongue neoplasms/drug therapy	0.8301902991225216	6.983302824892236e-14	0	1	0.010752688172043	1.1196757806633936e-12
tongue neoplasms/drug therapy	nivolumab/adverse effects	0.8301902991225216	0.0036027646835737	0	1	0.1290322580645161	0.0067591691408641
tongue neoplasms/drug therapy	paclitaxel/therapeutic use	0.8301902991225216	6.983302824892236e-14	0	1	0.010752688172043	1.1196757806633936e-12
tongue neoplasms/drug therapy	colitis ulcerative/chemically induced	0.8301902991225216	6.983302824892236e-14	0	1	0.010752688172043	1.1196757806633936e-12
tongue neoplasms/drug therapy	antineoplastic agents immunological/adverse effects	0.8301902991225216	0.0009302340538402	0	1	0.075268817204301	0.0021230700654632
paclitaxel/therapeutic use	nivolumab/adverse effects	0.8301902991225216	0.0036027646835737	0	1	0.1290322580645161	0.0067591691408641
paclitaxel/therapeutic use	colitis ulcerative/chemically induced	0.8301902991225216	6.983302824892236e-14	0	1	0.010752688172043	1.1196757806633936e-12
paclitaxel/therapeutic use	antineoplastic agents immunological/adverse effects	0.8301902991225216	0.0009302340538402	0	1	0.075268817204301	0.0021230700654632
colitis ulcerative/chemically induced	nivolumab/adverse effects	0.8301902991225216	0.0036027646835737	0	1	0.1290322580645161	0.0067591691408641
colitis ulcerative/chemically induced	antineoplastic agents immunological/adverse effects	0.8301902991225216	0.0009302340538402	0	1	0.075268817204301	0.0021230700654632
pneumonia	ligands	0.8301902991225216	0.0	0	1	0.010752688172043	0.0
inflammatory bowel diseases/drug therapy	carcinoma renal cell/drug therapy	0.8301902991225216	0.0012219719371479	0	1	0.0638148667601683	0.0026891839170452
inflammatory bowel diseases/drug therapy	proton pump inhibitors/adverse effects	0.8301902991225216	1.2526646386845641e-12	0	1	0.032258064516129	1.8672532270391784e-11
inflammatory bowel diseases/drug therapy	ipilimumab/therapeutic use	0.8301902991225216	0.0036027646835737	0	1	0.0946781129109319	0.0067591691408641
inflammatory bowel diseases/drug therapy	CD4	0.8301902991225216	0.0002334339983105	0	1	0.0638148667601683	0.0005814517869145
inflammatory bowel diseases/drug therapy	CD68	0.8301902991225216	0.0002334339983105	0	1	0.0638148667601683	0.0005814517869145
psoriasis	dermatitis	0.8301902991225216	1.6913137557139635e-11	0	1	0.010752688172043	1.9094832224273623e-10
psoriasis	rna	0.8301902991225216	1.6913137557139635e-11	0	1	0.010752688172043	1.9094832224273623e-10
psoriasis	CXCL10	0.8301902991225216	1.6913137557139635e-11	0	1	0.010752688172043	1.9094832224273623e-10
psoriasis	CXCL9	0.8301902991225216	1.6913137557139635e-11	0	1	0.010752688172043	1.9094832224273623e-10
psoriasis	TCIM	0.8301902991225216	1.6913137557139635e-11	0	1	0.010752688172043	1.9094832224273623e-10
dermatitis	rna	0.8301902991225216	1.6913137557139635e-11	0	1	0.010752688172043	1.9094832224273623e-10
dermatitis	CXCL10	0.8301902991225216	1.6913137557139635e-11	0	1	0.010752688172043	1.9094832224273623e-10
dermatitis	CXCL9	0.8301902991225216	1.6913137557139635e-11	0	1	0.010752688172043	1.9094832224273623e-10
dermatitis	TCIM	0.8301902991225216	1.6913137557139635e-11	0	1	0.010752688172043	1.9094832224273623e-10
rna	CXCL10	0.8301902991225216	1.6913137557139635e-11	0	1	0.010752688172043	1.9094832224273623e-10
rna	CXCL9	0.8301902991225216	1.6913137557139635e-11	0	1	0.010752688172043	1.9094832224273623e-10
rna	TCIM	0.8301902991225216	1.6913137557139635e-11	0	1	0.010752688172043	1.9094832224273623e-10
CXCL10	CXCL9	0.8301902991225216	1.6913137557139635e-11	0	1	0.010752688172043	1.9094832224273623e-10
CXCL10	TCIM	0.8301902991225216	1.6913137557139635e-11	0	1	0.010752688172043	1.9094832224273623e-10
CXCL9	TCIM	0.8301902991225216	1.6913137557139635e-11	0	1	0.010752688172043	1.9094832224273623e-10
interleukin-17/genetics	micrornas/genetics	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
interleukin-17/genetics	gene expression regulation neoplastic	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
interleukin-17/genetics	lymphocytes tumor-infiltrating/metabolism	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
interleukin-17/genetics	t-lymphocytes cytotoxic/immunology	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
interleukin-17/genetics	tumor microenvironment/drug effects	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
interleukin-17/genetics	ht29 cells	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
interleukin-17/genetics	colorectal neoplasms/drug therapy	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
interleukin-17/genetics	b7-h1 antigen/genetics	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
interleukin-17/genetics	APC	0.8301902991225216	0.0052154676801927	0	1	0.021505376344086	0.0095868134237069
interleukin-17/genetics	IL17A	0.8301902991225216	0.0017899010765538	0	1	0.021505376344086	0.0037694605453253
interleukin-17/genetics	MIR15B	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
interleukin-17/genetics	NRF1	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
micrornas/genetics	gene expression regulation neoplastic	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
micrornas/genetics	lymphocytes tumor-infiltrating/metabolism	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
micrornas/genetics	t-lymphocytes cytotoxic/immunology	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
micrornas/genetics	tumor microenvironment/drug effects	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
micrornas/genetics	ht29 cells	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
micrornas/genetics	colorectal neoplasms/drug therapy	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
micrornas/genetics	b7-h1 antigen/genetics	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
micrornas/genetics	APC	0.8301902991225216	0.0052154676801927	0	1	0.021505376344086	0.0095868134237069
micrornas/genetics	IL17A	0.8301902991225216	0.0017899010765538	0	1	0.021505376344086	0.0037694605453253
micrornas/genetics	MIR15B	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
micrornas/genetics	NRF1	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
gene expression regulation neoplastic	lymphocytes tumor-infiltrating/metabolism	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
gene expression regulation neoplastic	t-lymphocytes cytotoxic/immunology	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
gene expression regulation neoplastic	tumor microenvironment/drug effects	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
gene expression regulation neoplastic	ht29 cells	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
gene expression regulation neoplastic	colorectal neoplasms/drug therapy	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
gene expression regulation neoplastic	b7-h1 antigen/genetics	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
gene expression regulation neoplastic	APC	0.8301902991225216	0.0052154676801927	0	1	0.021505376344086	0.0095868134237069
gene expression regulation neoplastic	IL17A	0.8301902991225216	0.0017899010765538	0	1	0.021505376344086	0.0037694605453253
gene expression regulation neoplastic	MIR15B	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
gene expression regulation neoplastic	NRF1	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
lymphocytes tumor-infiltrating/metabolism	t-lymphocytes cytotoxic/immunology	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
lymphocytes tumor-infiltrating/metabolism	tumor microenvironment/drug effects	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
lymphocytes tumor-infiltrating/metabolism	ht29 cells	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
lymphocytes tumor-infiltrating/metabolism	colorectal neoplasms/drug therapy	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
lymphocytes tumor-infiltrating/metabolism	b7-h1 antigen/genetics	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
lymphocytes tumor-infiltrating/metabolism	APC	0.8301902991225216	0.0052154676801927	0	1	0.021505376344086	0.0095868134237069
lymphocytes tumor-infiltrating/metabolism	IL17A	0.8301902991225216	0.0017899010765538	0	1	0.021505376344086	0.0037694605453253
lymphocytes tumor-infiltrating/metabolism	MIR15B	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
lymphocytes tumor-infiltrating/metabolism	NRF1	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
t-lymphocytes cytotoxic/immunology	tumor microenvironment/drug effects	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
t-lymphocytes cytotoxic/immunology	ht29 cells	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
t-lymphocytes cytotoxic/immunology	colorectal neoplasms/drug therapy	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
t-lymphocytes cytotoxic/immunology	b7-h1 antigen/genetics	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
t-lymphocytes cytotoxic/immunology	APC	0.8301902991225216	0.0052154676801927	0	1	0.021505376344086	0.0095868134237069
t-lymphocytes cytotoxic/immunology	IL17A	0.8301902991225216	0.0017899010765538	0	1	0.021505376344086	0.0037694605453253
t-lymphocytes cytotoxic/immunology	MIR15B	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
t-lymphocytes cytotoxic/immunology	NRF1	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
tumor microenvironment/drug effects	ht29 cells	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
tumor microenvironment/drug effects	colorectal neoplasms/drug therapy	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
tumor microenvironment/drug effects	b7-h1 antigen/genetics	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
tumor microenvironment/drug effects	APC	0.8301902991225216	0.0052154676801927	0	1	0.021505376344086	0.0095868134237069
tumor microenvironment/drug effects	IL17A	0.8301902991225216	0.0017899010765538	0	1	0.021505376344086	0.0037694605453253
tumor microenvironment/drug effects	MIR15B	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
tumor microenvironment/drug effects	NRF1	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
ht29 cells	colorectal neoplasms/drug therapy	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
ht29 cells	b7-h1 antigen/genetics	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
ht29 cells	APC	0.8301902991225216	0.0052154676801927	0	1	0.021505376344086	0.0095868134237069
ht29 cells	IL17A	0.8301902991225216	0.0017899010765538	0	1	0.021505376344086	0.0037694605453253
ht29 cells	MIR15B	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
ht29 cells	NRF1	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
colorectal neoplasms/drug therapy	b7-h1 antigen/genetics	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
colorectal neoplasms/drug therapy	APC	0.8301902991225216	0.0052154676801927	0	1	0.021505376344086	0.0095868134237069
colorectal neoplasms/drug therapy	IL17A	0.8301902991225216	0.0017899010765538	0	1	0.021505376344086	0.0037694605453253
colorectal neoplasms/drug therapy	MIR15B	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
colorectal neoplasms/drug therapy	NRF1	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
b7-h1 antigen/genetics	APC	0.8301902991225216	0.0052154676801927	0	1	0.021505376344086	0.0095868134237069
b7-h1 antigen/genetics	IL17A	0.8301902991225216	0.0017899010765538	0	1	0.021505376344086	0.0037694605453253
b7-h1 antigen/genetics	MIR15B	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
b7-h1 antigen/genetics	NRF1	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
APC	immune checkpoint inhibitors/administration & dosage	0.5846350039324011	0.0022669618381826	0	2	0.0014025245441795	0.0045434487261055
APC	myeloid-derived suppressor cells/metabolism	0.8301902991225216	0.0028052417422615	0	1	0.021505376344086	0.005535058163635
APC	azoxymethane/adverse effects	0.8301902991225216	0.0028052417422615	0	1	0.021505376344086	0.005535058163635
APC	phthalazines/administration & dosage	0.8301902991225216	0.0028052417422615	0	1	0.021505376344086	0.005535058163635
APC	colonic neoplasms/drug therapy	0.8301902991225216	0.0028052417422615	0	1	0.021505376344086	0.005535058163635
APC	dextran sulfate/adverse effects	0.8301902991225216	0.0028052417422615	0	1	0.021505376344086	0.005535058163635
APC	poly(adp-ribose) polymerase inhibitors/administration & dosage	0.8301902991225216	0.0028052417422615	0	1	0.021505376344086	0.005535058163635
APC	piperazines/administration & dosage	0.8301902991225216	0.0028052417422615	0	1	0.021505376344086	0.005535058163635
APC	ARG1	0.8301902991225216	0.0028052417422615	0	1	0.021505376344086	0.005535058163635
APC	MIR15B	0.8301902991225216	0.0052154676801927	0	1	0.021505376344086	0.0095868134237069
APC	NRF1	0.8301902991225216	0.0052154676801927	0	1	0.021505376344086	0.0095868134237069
APC	PARP1	0.8301902991225216	0.0028052417422615	0	1	0.021505376344086	0.005535058163635
APC	TIPARP	0.8301902991225216	0.0028052417422615	0	1	0.021505376344086	0.005535058163635
IL17A	MIR15B	0.8301902991225216	0.0017899010765538	0	1	0.021505376344086	0.0037694605453253
IL17A	NRF1	0.8301902991225216	0.0017899010765538	0	1	0.021505376344086	0.0037694605453253
MIR15B	NRF1	0.8301902991225216	9.37505645396408e-05	0	1	0.010752688172043	0.0002777578837603
feces	steroids/therapeutic use	0.8301902991225216	0.0	0	1	0.021505376344086	0.0
feces	dose-response relationship drug	0.8301902991225216	7.771561172376097e-16	0	1	0.021505376344086	1.6660830018981562e-14
feces/chemistry	colitis/drug therapy	0.8301902991225216	2.2507388619530392e-08	0	1	0.032258064516129	1.5068104381075084e-07
feces/chemistry	leukocyte l1 antigen complex/analysis	0.8301902991225216	0.0	0	1	0.010752688172043	0.0
feces/chemistry	biomarkers/analysis	0.8301902991225216	0.0	0	1	0.010752688172043	0.0
leukocyte l1 antigen complex/analysis	colitis/drug therapy	0.8301902991225216	2.2507388619530392e-08	0	1	0.032258064516129	1.5068104381075084e-07
leukocyte l1 antigen complex/analysis	biomarkers/analysis	0.8301902991225216	0.0	0	1	0.010752688172043	0.0
biomarkers/analysis	colitis/drug therapy	0.8301902991225216	2.2507388619530392e-08	0	1	0.032258064516129	1.5068104381075084e-07
nivolumab/adverse effects	immune checkpoint inhibitors/adverse effects	0.0008903144156418	0.0016934163344379	0	9	0.1495736622090809	0.0036716345069405
nivolumab/adverse effects	lung neoplasms/drug therapy	0.8301902991225216	0.0036027646835737	0	1	0.2426367461430575	0.0067591691408641
nivolumab/adverse effects	protein kinase inhibitors/therapeutic use	0.8301902991225216	0.000872653019809	0	1	0.1290322580645161	0.0020084704002361
nivolumab/adverse effects	ipilimumab/adverse effects	0.010308700389748	0.0	0	7	2.7098127426765173e-06	0.0
nivolumab/adverse effects	oropharyngeal neoplasms/drug therapy	0.8301902991225216	8.279835420732518e-06	0	1	0.1290322580645161	3.540508179502065e-05
nivolumab/adverse effects	disease susceptibility	0.8301902991225216	8.279835420732518e-06	0	1	0.1290322580645161	3.540508179502065e-05
nivolumab/adverse effects	drug-related side effects and adverse reactions/diagnosis	0.8301902991225216	0.0003058560984983	0	1	0.1290322580645161	0.0007520276236272
nivolumab/adverse effects	postoperative complications	0.8301902991225216	8.279835420732518e-06	0	1	0.1290322580645161	3.540508179502065e-05
immune checkpoint inhibitors/adverse effects	antineoplastic agents immunological/adverse effects	0.010308700389748	0.0053254060985574	0	7	0.016270764526575	0.0097794752993721
ipilimumab/adverse effects	protein kinase inhibitors/therapeutic use	0.8301902991225216	8.840970615020538e-05	0	1	0.0967741935483871	0.0002777578837603
ipilimumab/adverse effects	drug-related side effects and adverse reactions/diagnosis	0.8301902991225216	2.1656343085596497e-05	0	1	0.0967741935483871	8.149961066532172e-05
drug-related side effects and adverse reactions/prevention & control	growth inhibitors/therapeutic use	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
drug-related side effects and adverse reactions/prevention & control	phosphatidylinositol 3-kinases/metabolism	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
drug-related side effects and adverse reactions/prevention & control	lymphocytes tumor-infiltrating/immunology	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
drug-related side effects and adverse reactions/prevention & control	colitis/etiology	0.8301902991225216	0.000267839978386	0	1	0.021505376344086	0.0006602566909052
drug-related side effects and adverse reactions/prevention & control	immune checkpoint inhibitors/therapeutic use	0.8301902991225216	0.0032890445713762	0	1	0.021505376344086	0.0063197351885054
drug-related side effects and adverse reactions/prevention & control	cell line tumor	0.8301902991225216	0.0019794334203299	0	1	0.021505376344086	0.0040050466235307
drug-related side effects and adverse reactions/prevention & control	cd8-positive t-lymphocytes/immunology	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
drug-related side effects and adverse reactions/prevention & control	cytotoxicity immunologic	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
drug-related side effects and adverse reactions/prevention & control	MTOR	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
drug-related side effects and adverse reactions/prevention & control	sirolimus/therapeutic use	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
drug-related side effects and adverse reactions/prevention & control	drug synergism	0.8301902991225216	0.0019794334203299	0	1	0.021505376344086	0.0040050466235307
growth inhibitors/therapeutic use	sirolimus/therapeutic use	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
growth inhibitors/therapeutic use	drug synergism	0.8301902991225216	0.0019794334203299	0	1	0.021505376344086	0.0040050466235307
growth inhibitors/therapeutic use	phosphatidylinositol 3-kinases/metabolism	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
growth inhibitors/therapeutic use	lymphocytes tumor-infiltrating/immunology	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
growth inhibitors/therapeutic use	colitis/etiology	0.8301902991225216	0.000267839978386	0	1	0.021505376344086	0.0006602566909052
growth inhibitors/therapeutic use	immune checkpoint inhibitors/therapeutic use	0.8301902991225216	0.0032890445713762	0	1	0.021505376344086	0.0063197351885054
growth inhibitors/therapeutic use	cell line tumor	0.8301902991225216	0.0019794334203299	0	1	0.021505376344086	0.0040050466235307
growth inhibitors/therapeutic use	cd8-positive t-lymphocytes/immunology	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
growth inhibitors/therapeutic use	cytotoxicity immunologic	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
growth inhibitors/therapeutic use	MTOR	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
phosphatidylinositol 3-kinases/metabolism	sirolimus/therapeutic use	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
phosphatidylinositol 3-kinases/metabolism	drug synergism	0.8301902991225216	0.0019794334203299	0	1	0.021505376344086	0.0040050466235307
phosphatidylinositol 3-kinases/metabolism	lymphocytes tumor-infiltrating/immunology	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
phosphatidylinositol 3-kinases/metabolism	colitis/etiology	0.8301902991225216	0.000267839978386	0	1	0.021505376344086	0.0006602566909052
phosphatidylinositol 3-kinases/metabolism	immune checkpoint inhibitors/therapeutic use	0.8301902991225216	0.0032890445713762	0	1	0.021505376344086	0.0063197351885054
phosphatidylinositol 3-kinases/metabolism	cell line tumor	0.8301902991225216	0.0019794334203299	0	1	0.021505376344086	0.0040050466235307
phosphatidylinositol 3-kinases/metabolism	cd8-positive t-lymphocytes/immunology	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
phosphatidylinositol 3-kinases/metabolism	cytotoxicity immunologic	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
phosphatidylinositol 3-kinases/metabolism	MTOR	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
lymphocytes tumor-infiltrating/immunology	sirolimus/therapeutic use	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
lymphocytes tumor-infiltrating/immunology	drug synergism	0.8301902991225216	0.0019794334203299	0	1	0.021505376344086	0.0040050466235307
lymphocytes tumor-infiltrating/immunology	colitis/etiology	0.8301902991225216	0.000267839978386	0	1	0.021505376344086	0.0006602566909052
lymphocytes tumor-infiltrating/immunology	immune checkpoint inhibitors/therapeutic use	0.8301902991225216	0.0032890445713762	0	1	0.021505376344086	0.0063197351885054
lymphocytes tumor-infiltrating/immunology	cell line tumor	0.8301902991225216	0.0019794334203299	0	1	0.021505376344086	0.0040050466235307
lymphocytes tumor-infiltrating/immunology	cd8-positive t-lymphocytes/immunology	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
lymphocytes tumor-infiltrating/immunology	cytotoxicity immunologic	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
lymphocytes tumor-infiltrating/immunology	MTOR	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
colitis/etiology	host microbial interactions/drug effects	0.8301902991225216	6.548312436738257e-08	0	1	0.021505376344086	4.308337975619515e-07
colitis/etiology	sirolimus/therapeutic use	0.8301902991225216	0.000267839978386	0	1	0.021505376344086	0.0006602566909052
colitis/etiology	metabolome/drug effects	0.8301902991225216	6.548312436738257e-08	0	1	0.021505376344086	4.308337975619515e-07
colitis/etiology	dysbiosis/etiology	0.8301902991225216	6.548312436738257e-08	0	1	0.021505376344086	4.308337975619515e-07
colitis/etiology	neoplasms/complications	0.8301902991225216	0.0012943475198039	0	1	0.0638148667601683	0.0028224172203267
colitis/etiology	cd8-positive t-lymphocytes/immunology	0.8301902991225216	0.000267839978386	0	1	0.021505376344086	0.0006602566909052
colitis/etiology	anti-bacterial agents/pharmacology	0.8301902991225216	6.548312436738257e-08	0	1	0.021505376344086	4.308337975619515e-07
colitis/etiology	cytotoxicity immunologic	0.8301902991225216	0.000267839978386	0	1	0.021505376344086	0.0006602566909052
colitis/etiology	MTOR	0.8301902991225216	0.000267839978386	0	1	0.021505376344086	0.0006602566909052
immune checkpoint inhibitors/therapeutic use	sirolimus/therapeutic use	0.8301902991225216	0.0032890445713762	0	1	0.021505376344086	0.0063197351885054
immune checkpoint inhibitors/therapeutic use	cd8-positive t-lymphocytes/immunology	0.8301902991225216	0.0032890445713762	0	1	0.021505376344086	0.0063197351885054
immune checkpoint inhibitors/therapeutic use	cytotoxicity immunologic	0.8301902991225216	0.0032890445713762	0	1	0.021505376344086	0.0063197351885054
immune checkpoint inhibitors/therapeutic use	MTOR	0.8301902991225216	0.0032890445713762	0	1	0.021505376344086	0.0063197351885054
cell line tumor	myeloid-derived suppressor cells/metabolism	0.8301902991225216	0.0019794334203299	0	1	0.021505376344086	0.0040050466235307
cell line tumor	sirolimus/therapeutic use	0.8301902991225216	0.0019794334203299	0	1	0.021505376344086	0.0040050466235307
cell line tumor	drug synergism	0.5846350039324011	2.300421797984953e-05	0	2	0.0002337540906965	8.623192122898408e-05
cell line tumor	azoxymethane/adverse effects	0.8301902991225216	0.0019794334203299	0	1	0.021505376344086	0.0040050466235307
cell line tumor	phthalazines/administration & dosage	0.8301902991225216	0.0019794334203299	0	1	0.021505376344086	0.0040050466235307
cell line tumor	colonic neoplasms/drug therapy	0.8301902991225216	0.0019794334203299	0	1	0.021505376344086	0.0040050466235307
cell line tumor	dextran sulfate/adverse effects	0.8301902991225216	0.0019794334203299	0	1	0.021505376344086	0.0040050466235307
cell line tumor	poly(adp-ribose) polymerase inhibitors/administration & dosage	0.8301902991225216	0.0019794334203299	0	1	0.021505376344086	0.0040050466235307
cell line tumor	cd8-positive t-lymphocytes/immunology	0.8301902991225216	0.0019794334203299	0	1	0.021505376344086	0.0040050466235307
cell line tumor	piperazines/administration & dosage	0.8301902991225216	0.0019794334203299	0	1	0.021505376344086	0.0040050466235307
cell line tumor	cytotoxicity immunologic	0.8301902991225216	0.0019794334203299	0	1	0.021505376344086	0.0040050466235307
cell line tumor	ARG1	0.8301902991225216	0.0019794334203299	0	1	0.021505376344086	0.0040050466235307
cell line tumor	MTOR	0.8301902991225216	0.0019794334203299	0	1	0.021505376344086	0.0040050466235307
cell line tumor	PARP1	0.8301902991225216	0.0019794334203299	0	1	0.021505376344086	0.0040050466235307
cell line tumor	TIPARP	0.8301902991225216	0.0019794334203299	0	1	0.021505376344086	0.0040050466235307
cd8-positive t-lymphocytes/immunology	sirolimus/therapeutic use	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
cd8-positive t-lymphocytes/immunology	drug synergism	0.8301902991225216	0.0019794334203299	0	1	0.021505376344086	0.0040050466235307
cd8-positive t-lymphocytes/immunology	cytotoxicity immunologic	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
cd8-positive t-lymphocytes/immunology	MTOR	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
cytotoxicity immunologic	sirolimus/therapeutic use	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
cytotoxicity immunologic	drug synergism	0.8301902991225216	0.0019794334203299	0	1	0.021505376344086	0.0040050466235307
cytotoxicity immunologic	MTOR	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
MTOR	sirolimus/therapeutic use	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
MTOR	drug synergism	0.8301902991225216	0.0019794334203299	0	1	0.021505376344086	0.0040050466235307
sirolimus/therapeutic use	drug synergism	0.8301902991225216	0.0019794334203299	0	1	0.021505376344086	0.0040050466235307
drug synergism	myeloid-derived suppressor cells/metabolism	0.8301902991225216	0.0019794334203299	0	1	0.021505376344086	0.0040050466235307
drug synergism	azoxymethane/adverse effects	0.8301902991225216	0.0019794334203299	0	1	0.021505376344086	0.0040050466235307
drug synergism	phthalazines/administration & dosage	0.8301902991225216	0.0019794334203299	0	1	0.021505376344086	0.0040050466235307
drug synergism	dextran sulfate/adverse effects	0.8301902991225216	0.0019794334203299	0	1	0.021505376344086	0.0040050466235307
drug synergism	colonic neoplasms/drug therapy	0.8301902991225216	0.0019794334203299	0	1	0.021505376344086	0.0040050466235307
drug synergism	poly(adp-ribose) polymerase inhibitors/administration & dosage	0.8301902991225216	0.0019794334203299	0	1	0.021505376344086	0.0040050466235307
drug synergism	piperazines/administration & dosage	0.8301902991225216	0.0019794334203299	0	1	0.021505376344086	0.0040050466235307
drug synergism	ARG1	0.8301902991225216	0.0019794334203299	0	1	0.021505376344086	0.0040050466235307
drug synergism	PARP1	0.8301902991225216	0.0019794334203299	0	1	0.021505376344086	0.0040050466235307
drug synergism	TIPARP	0.8301902991225216	0.0019794334203299	0	1	0.021505376344086	0.0040050466235307
colitis/diagnosis	disease susceptibility	0.8301902991225216	0.0	0	1	0.021505376344086	0.0
colitis/diagnosis	postoperative complications	0.8301902991225216	0.0	0	1	0.021505376344086	0.0
colitis/diagnosis	gastrointestinal tract/metabolism	0.8301902991225216	1.5654144647214707e-14	0	1	0.021505376344086	3.177458296477198e-13
colitis/diagnosis	b7-h1 antigen/metabolism	0.8301902991225216	1.5654144647214707e-14	0	1	0.021505376344086	3.177458296477198e-13
colitis/diagnosis	programmed cell death 1 receptor/metabolism	0.8301902991225216	1.5654144647214707e-14	0	1	0.021505376344086	3.177458296477198e-13
programmed cell death 1 receptor/metabolism	gastrointestinal tract/metabolism	0.8301902991225216	0.0	0	1	0.010752688172043	0.0
programmed cell death 1 receptor/metabolism	b7-h1 antigen/metabolism	0.8301902991225216	0.0	0	1	0.010752688172043	0.0
gastrointestinal tract/metabolism	b7-h1 antigen/metabolism	0.8301902991225216	0.0	0	1	0.010752688172043	0.0
immune checkpoint inhibitors/administration & dosage	urothelium/drug effects	0.8301902991225216	0.000872653019809	0	1	0.043010752688172	0.0020084704002361
immune checkpoint inhibitors/administration & dosage	neoplasms/diagnosis	0.8301902991225216	0.0017670866860923	0	1	0.043010752688172	0.0037694605453253
immune checkpoint inhibitors/administration & dosage	antibodies monoclonal humanized/administration & dosage	0.8301902991225216	0.0017670866860923	0	1	0.043010752688172	0.0037694605453253
immune checkpoint inhibitors/administration & dosage	carcinoma non-small-cell lung/complications	0.8301902991225216	0.000872653019809	0	1	0.043010752688172	0.0020084704002361
immune checkpoint inhibitors/administration & dosage	infliximab/administration & dosage	0.8301902991225216	0.000872653019809	0	1	0.043010752688172	0.0020084704002361
immune checkpoint inhibitors/administration & dosage	drugs investigational/administration & dosage	0.8301902991225216	0.0017670866860923	0	1	0.043010752688172	0.0037694605453253
immune checkpoint inhibitors/administration & dosage	CRP	0.8301902991225216	0.000872653019809	0	1	0.043010752688172	0.0020084704002361
urothelium/drug effects	carcinoma non-small-cell lung/complications	0.8301902991225216	0.0	0	1	0.010752688172043	0.0
urothelium/drug effects	melanoma/complications	0.8301902991225216	8.113733580561444e-07	0	1	0.032258064516129	4.852979207432989e-06
urothelium/drug effects	infliximab/administration & dosage	0.8301902991225216	0.0	0	1	0.010752688172043	0.0
urothelium/drug effects	CRP	0.8301902991225216	0.0	0	1	0.010752688172043	0.0
neoplasms/diagnosis	pneumonia/chemically induced	0.8301902991225216	9.105000230447136e-05	0	1	0.032258064516129	0.0002777578837603
neoplasms/diagnosis	antibodies monoclonal humanized/administration & dosage	0.8301902991225216	6.983302824892236e-14	0	1	0.010752688172043	1.1196757806633936e-12
neoplasms/diagnosis	dose-response relationship drug	0.8301902991225216	2.1620795154220222e-09	0	1	0.021505376344086	1.6435249862251864e-08
neoplasms/diagnosis	drugs investigational/administration & dosage	0.8301902991225216	6.983302824892236e-14	0	1	0.010752688172043	1.1196757806633936e-12
antibodies monoclonal humanized/administration & dosage	pneumonia/chemically induced	0.8301902991225216	9.105000230447136e-05	0	1	0.032258064516129	0.0002777578837603
antibodies monoclonal humanized/administration & dosage	dose-response relationship drug	0.8301902991225216	2.1620795154220222e-09	0	1	0.021505376344086	1.6435249862251864e-08
antibodies monoclonal humanized/administration & dosage	drugs investigational/administration & dosage	0.8301902991225216	6.983302824892236e-14	0	1	0.010752688172043	1.1196757806633936e-12
carcinoma non-small-cell lung/complications	melanoma/complications	0.8301902991225216	8.113733580561444e-07	0	1	0.032258064516129	4.852979207432989e-06
carcinoma non-small-cell lung/complications	infliximab/administration & dosage	0.8301902991225216	0.0	0	1	0.010752688172043	0.0
carcinoma non-small-cell lung/complications	CRP	0.8301902991225216	0.0	0	1	0.010752688172043	0.0
infliximab/administration & dosage	melanoma/complications	0.8301902991225216	8.113733580561444e-07	0	1	0.032258064516129	4.852979207432989e-06
infliximab/administration & dosage	CRP	0.8301902991225216	0.0	0	1	0.010752688172043	0.0
drugs investigational/administration & dosage	pneumonia/chemically induced	0.8301902991225216	9.105000230447136e-05	0	1	0.032258064516129	0.0002777578837603
drugs investigational/administration & dosage	dose-response relationship drug	0.8301902991225216	2.1620795154220222e-09	0	1	0.021505376344086	1.6435249862251864e-08
CRP	melanoma/complications	0.8301902991225216	8.113733580561444e-07	0	1	0.032258064516129	4.852979207432989e-06
antineoplastic agents immunological/therapeutic use	glucocorticoids/therapeutic use	0.8301902991225216	0.0005888664151666	0	1	0.032258064516129	0.0013888221509739
antineoplastic agents immunological/therapeutic use	disease progression	0.8301902991225216	0.0005888664151666	0	1	0.032258064516129	0.0013888221509739
antineoplastic agents immunological/therapeutic use	abdominal pain/chemically induced	0.8301902991225216	0.0005888664151666	0	1	0.032258064516129	0.0013888221509739
antineoplastic agents immunological/therapeutic use	gastritis/complications	0.8301902991225216	0.0005888664151666	0	1	0.032258064516129	0.0013888221509739
antineoplastic agents immunological/therapeutic use	enterocolitis/chemically induced	0.8301902991225216	0.0031884016641496	0	1	0.0638148667601683	0.0061761120560381
glucocorticoids/therapeutic use	disease progression	0.8301902991225216	6.983302824892236e-14	0	1	0.010752688172043	1.1196757806633936e-12
glucocorticoids/therapeutic use	abdominal pain/chemically induced	0.8301902991225216	6.983302824892236e-14	0	1	0.010752688172043	1.1196757806633936e-12
glucocorticoids/therapeutic use	gastritis/complications	0.8301902991225216	6.983302824892236e-14	0	1	0.010752688172043	1.1196757806633936e-12
glucocorticoids/therapeutic use	enterocolitis/chemically induced	0.8301902991225216	9.620737539961509e-11	0	1	0.021505376344086	1.0197981792359201e-09
disease progression	abdominal pain/chemically induced	0.8301902991225216	6.983302824892236e-14	0	1	0.010752688172043	1.1196757806633936e-12
disease progression	gastritis/complications	0.8301902991225216	6.983302824892236e-14	0	1	0.010752688172043	1.1196757806633936e-12
disease progression	enterocolitis/chemically induced	0.8301902991225216	9.620737539961509e-11	0	1	0.021505376344086	1.0197981792359201e-09
abdominal pain/chemically induced	gastritis/complications	0.8301902991225216	6.983302824892236e-14	0	1	0.010752688172043	1.1196757806633936e-12
abdominal pain/chemically induced	enterocolitis/chemically induced	0.8301902991225216	9.620737539961509e-11	0	1	0.021505376344086	1.0197981792359201e-09
gastritis/complications	enterocolitis/chemically induced	0.8301902991225216	9.620737539961509e-11	0	1	0.021505376344086	1.0197981792359201e-09
enterocolitis/chemically induced	colitis ulcerative/physiopathology	0.8301902991225216	0.0	0	1	0.021505376344086	0.0
enterocolitis/chemically induced	crohn disease/physiopathology	0.8301902991225216	0.0	0	1	0.021505376344086	0.0
host microbial interactions/drug effects	antineoplastic agents immunological/adverse effects	0.8301902991225216	0.0001577274046907	0	1	0.075268817204301	0.0004491699823134
host microbial interactions/drug effects	metabolome/drug effects	0.8301902991225216	0.0	0	1	0.010752688172043	0.0
host microbial interactions/drug effects	dysbiosis/etiology	0.8301902991225216	0.0	0	1	0.010752688172043	0.0
host microbial interactions/drug effects	neoplasms/complications	0.8301902991225216	5.791998547444166e-09	0	1	0.032258064516129	4.186035313834648e-08
host microbial interactions/drug effects	anti-bacterial agents/pharmacology	0.8301902991225216	0.0	0	1	0.010752688172043	0.0
metabolome/drug effects	antineoplastic agents immunological/adverse effects	0.8301902991225216	0.0001577274046907	0	1	0.075268817204301	0.0004491699823134
metabolome/drug effects	dysbiosis/etiology	0.8301902991225216	0.0	0	1	0.010752688172043	0.0
metabolome/drug effects	neoplasms/complications	0.8301902991225216	5.791998547444166e-09	0	1	0.032258064516129	4.186035313834648e-08
metabolome/drug effects	anti-bacterial agents/pharmacology	0.8301902991225216	0.0	0	1	0.010752688172043	0.0
dysbiosis/etiology	antineoplastic agents immunological/adverse effects	0.8301902991225216	0.0001577274046907	0	1	0.075268817204301	0.0004491699823134
dysbiosis/etiology	neoplasms/complications	0.8301902991225216	5.791998547444166e-09	0	1	0.032258064516129	4.186035313834648e-08
dysbiosis/etiology	anti-bacterial agents/pharmacology	0.8301902991225216	0.0	0	1	0.010752688172043	0.0
neoplasms/complications	b7-h1 antigen/antagonists & inhibitors	0.8301902991225216	0.0007148389160953	0	1	0.0946781129109319	0.0016572450205467
neoplasms/complications	colitis/epidemiology	0.8301902991225216	3.0242941484459607e-10	0	1	0.032258064516129	3.119109856883726e-09
neoplasms/complications	inflammatory bowel diseases/complications	0.8301902991225216	3.032920734558076e-07	0	1	0.0638148667601683	1.9550043113300028e-06
neoplasms/complications	anti-bacterial agents/pharmacology	0.8301902991225216	5.791998547444166e-09	0	1	0.032258064516129	4.186035313834648e-08
anti-bacterial agents/pharmacology	antineoplastic agents immunological/adverse effects	0.8301902991225216	0.0001577274046907	0	1	0.075268817204301	0.0004491699823134
programmed cell death 1 receptor/antagonists & inhibitors	b7-h1 antigen/antagonists & inhibitors	0.5846350039324011	0.0023776856511018	0	2	0.0187722515913259	0.0047603611986383
programmed cell death 1 receptor/antagonists & inhibitors	colitis/epidemiology	0.8301902991225216	0.0026251685810957	0	1	0.086021505376344	0.0052393531932329
programmed cell death 1 receptor/antagonists & inhibitors	ctla-4 antigen/antagonists & inhibitors	0.3479096080556238	0.0004806528722617	0	3	0.0004315460135936	0.0011594003543304
programmed cell death 1 receptor/antagonists & inhibitors	antineoplastic agents immunological/adverse effects	0.3479096080556238	0.0049629267011769	0	3	0.012719967331643	0.0092203156239976
b7-h1 antigen/antagonists & inhibitors	glycoproteins/metabolism	0.8301902991225216	8.488771907622095e-10	0	1	0.032258064516129	7.743202371973273e-09
b7-h1 antigen/antagonists & inhibitors	biomarkers/metabolism	0.8301902991225216	8.488771907622095e-10	0	1	0.032258064516129	7.743202371973273e-09
b7-h1 antigen/antagonists & inhibitors	adenocarcinoma of lung/drug therapy	0.8301902991225216	8.488771907622095e-10	0	1	0.032258064516129	7.743202371973273e-09
b7-h1 antigen/antagonists & inhibitors	colitis/epidemiology	0.8301902991225216	8.488771907622095e-10	0	1	0.032258064516129	7.743202371973273e-09
ctla-4 antigen/antagonists & inhibitors	antineoplastic agents immunological/adverse effects	0.5846350039324011	0.0011131493251242	0	2	0.0141870751968928	0.0025284391813537
ctla-4 antigen/antagonists & inhibitors	interferon-gamma/metabolism	0.8301902991225216	0.0012578068210133	0	1	0.032258064516129	0.0027490210933488
ctla-4 antigen/antagonists & inhibitors	immunologic memory/drug effects	0.8301902991225216	0.0012578068210133	0	1	0.032258064516129	0.0027490210933488
ctla-4 antigen/antagonists & inhibitors	lymphocytes/drug effects	0.8301902991225216	0.000426487876034	0	1	0.032258064516129	0.0010339756892922
ctla-4 antigen/antagonists & inhibitors	vitamin d/administration & dosage	0.8301902991225216	0.000426487876034	0	1	0.032258064516129	0.0010339756892922
ctla-4 antigen/antagonists & inhibitors	neutrophils/drug effects	0.8301902991225216	0.000426487876034	0	1	0.032258064516129	0.0010339756892922
ctla-4 antigen/antagonists & inhibitors	antibodies monoclonal/adverse effects	0.8301902991225216	0.000426487876034	0	1	0.032258064516129	0.0010339756892922
antineoplastic agents immunological/adverse effects	vitamin d	0.8301902991225216	4.503715761439153e-07	0	1	0.075268817204301	2.8739430343899343e-06
antineoplastic agents immunological/adverse effects	lymphocytes/drug effects	0.8301902991225216	0.0029295317826157	0	1	0.075268817204301	0.0057564846974571
antineoplastic agents immunological/adverse effects	vitamin d/administration & dosage	0.8301902991225216	0.0029295317826157	0	1	0.075268817204301	0.0057564846974571
antineoplastic agents immunological/adverse effects	cytomegalovirus infections/diagnosis	0.8301902991225216	5.063311991904129e-09	0	1	0.075268817204301	3.715692030981953e-08
antineoplastic agents immunological/adverse effects	neutrophils/drug effects	0.8301902991225216	0.0029295317826157	0	1	0.075268817204301	0.0057564846974571
antineoplastic agents immunological/adverse effects	antibodies monoclonal/adverse effects	0.8301902991225216	0.0029295317826157	0	1	0.075268817204301	0.0057564846974571
myeloid-derived suppressor cells/metabolism	azoxymethane/adverse effects	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
myeloid-derived suppressor cells/metabolism	phthalazines/administration & dosage	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
myeloid-derived suppressor cells/metabolism	dextran sulfate/adverse effects	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
myeloid-derived suppressor cells/metabolism	colonic neoplasms/drug therapy	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
myeloid-derived suppressor cells/metabolism	poly(adp-ribose) polymerase inhibitors/administration & dosage	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
myeloid-derived suppressor cells/metabolism	piperazines/administration & dosage	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
myeloid-derived suppressor cells/metabolism	ARG1	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
myeloid-derived suppressor cells/metabolism	PARP1	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
myeloid-derived suppressor cells/metabolism	TIPARP	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
azoxymethane/adverse effects	phthalazines/administration & dosage	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
azoxymethane/adverse effects	dextran sulfate/adverse effects	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
azoxymethane/adverse effects	colonic neoplasms/drug therapy	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
azoxymethane/adverse effects	poly(adp-ribose) polymerase inhibitors/administration & dosage	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
azoxymethane/adverse effects	piperazines/administration & dosage	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
azoxymethane/adverse effects	ARG1	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
azoxymethane/adverse effects	PARP1	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
azoxymethane/adverse effects	TIPARP	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
phthalazines/administration & dosage	poly(adp-ribose) polymerase inhibitors/administration & dosage	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
phthalazines/administration & dosage	piperazines/administration & dosage	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
phthalazines/administration & dosage	ARG1	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
phthalazines/administration & dosage	PARP1	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
phthalazines/administration & dosage	TIPARP	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
phthalazines/administration & dosage	dextran sulfate/adverse effects	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
phthalazines/administration & dosage	colonic neoplasms/drug therapy	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
colonic neoplasms/drug therapy	dextran sulfate/adverse effects	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
colonic neoplasms/drug therapy	poly(adp-ribose) polymerase inhibitors/administration & dosage	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
colonic neoplasms/drug therapy	piperazines/administration & dosage	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
colonic neoplasms/drug therapy	ARG1	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
colonic neoplasms/drug therapy	PARP1	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
colonic neoplasms/drug therapy	TIPARP	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
dextran sulfate/adverse effects	poly(adp-ribose) polymerase inhibitors/administration & dosage	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
dextran sulfate/adverse effects	piperazines/administration & dosage	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
dextran sulfate/adverse effects	ARG1	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
dextran sulfate/adverse effects	PARP1	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
dextran sulfate/adverse effects	TIPARP	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
poly(adp-ribose) polymerase inhibitors/administration & dosage	piperazines/administration & dosage	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
poly(adp-ribose) polymerase inhibitors/administration & dosage	ARG1	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
poly(adp-ribose) polymerase inhibitors/administration & dosage	PARP1	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
poly(adp-ribose) polymerase inhibitors/administration & dosage	TIPARP	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
piperazines/administration & dosage	ARG1	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
piperazines/administration & dosage	PARP1	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
piperazines/administration & dosage	TIPARP	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
ARG1	PARP1	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
ARG1	TIPARP	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
PARP1	TIPARP	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
nephritis/chemically induced	nivolumab/therapeutic use	0.8301902991225216	0.00299295859196	0	1	0.021505376344086	0.0058034197088005
nephritis/chemically induced	carcinoma renal cell/drug therapy	0.8301902991225216	0.0012219719371479	0	1	0.021505376344086	0.0026891839170452
nephritis/chemically induced	diabetes mellitus type 1/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
nephritis/chemically induced	exanthema/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
nephritis/chemically induced	bevacizumab/administration & dosage	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
nephritis/chemically induced	fatigue/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
nephritis/chemically induced	pruritus/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
nephritis/chemically induced	adrenal insufficiency/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
nephritis/chemically induced	axitinib/administration & dosage	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
nephritis/chemically induced	hypophysitis/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
nephritis/chemically induced	angiogenesis inhibitors/therapeutic use	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
nephritis/chemically induced	myocarditis/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
nephritis/chemically induced	hepatitis autoimmune/etiology	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
nephritis/chemically induced	myasthenia gravis/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
nephritis/chemically induced	ipilimumab/therapeutic use	0.8301902991225216	0.0036027646835737	0	1	0.032258064516129	0.0067591691408641
nivolumab/therapeutic use	diabetes mellitus type 1/chemically induced	0.8301902991225216	0.00299295859196	0	1	0.021505376344086	0.0058034197088005
nivolumab/therapeutic use	exanthema/chemically induced	0.8301902991225216	0.00299295859196	0	1	0.021505376344086	0.0058034197088005
nivolumab/therapeutic use	bevacizumab/administration & dosage	0.8301902991225216	0.00299295859196	0	1	0.021505376344086	0.0058034197088005
nivolumab/therapeutic use	fatigue/chemically induced	0.8301902991225216	0.00299295859196	0	1	0.021505376344086	0.0058034197088005
nivolumab/therapeutic use	pruritus/chemically induced	0.8301902991225216	0.00299295859196	0	1	0.021505376344086	0.0058034197088005
nivolumab/therapeutic use	adrenal insufficiency/chemically induced	0.8301902991225216	0.00299295859196	0	1	0.021505376344086	0.0058034197088005
nivolumab/therapeutic use	axitinib/administration & dosage	0.8301902991225216	0.00299295859196	0	1	0.021505376344086	0.0058034197088005
nivolumab/therapeutic use	hypophysitis/chemically induced	0.8301902991225216	0.00299295859196	0	1	0.021505376344086	0.0058034197088005
nivolumab/therapeutic use	angiogenesis inhibitors/therapeutic use	0.8301902991225216	0.00299295859196	0	1	0.021505376344086	0.0058034197088005
nivolumab/therapeutic use	myocarditis/chemically induced	0.8301902991225216	0.00299295859196	0	1	0.021505376344086	0.0058034197088005
nivolumab/therapeutic use	hepatitis autoimmune/etiology	0.8301902991225216	0.00299295859196	0	1	0.021505376344086	0.0058034197088005
nivolumab/therapeutic use	myasthenia gravis/chemically induced	0.8301902991225216	0.00299295859196	0	1	0.021505376344086	0.0058034197088005
carcinoma renal cell/drug therapy	diabetes mellitus type 1/chemically induced	0.8301902991225216	0.0012219719371479	0	1	0.021505376344086	0.0026891839170452
carcinoma renal cell/drug therapy	exanthema/chemically induced	0.8301902991225216	0.0012219719371479	0	1	0.021505376344086	0.0026891839170452
carcinoma renal cell/drug therapy	bevacizumab/administration & dosage	0.8301902991225216	0.0012219719371479	0	1	0.021505376344086	0.0026891839170452
carcinoma renal cell/drug therapy	fatigue/chemically induced	0.8301902991225216	0.0012219719371479	0	1	0.021505376344086	0.0026891839170452
carcinoma renal cell/drug therapy	pruritus/chemically induced	0.8301902991225216	0.0012219719371479	0	1	0.021505376344086	0.0026891839170452
carcinoma renal cell/drug therapy	adrenal insufficiency/chemically induced	0.8301902991225216	0.0012219719371479	0	1	0.021505376344086	0.0026891839170452
carcinoma renal cell/drug therapy	axitinib/administration & dosage	0.8301902991225216	0.0012219719371479	0	1	0.021505376344086	0.0026891839170452
carcinoma renal cell/drug therapy	proton pump inhibitors/adverse effects	0.8301902991225216	3.618567667729167e-10	0	1	0.021505376344086	3.711950059154435e-09
carcinoma renal cell/drug therapy	hypophysitis/chemically induced	0.8301902991225216	0.0012219719371479	0	1	0.021505376344086	0.0026891839170452
carcinoma renal cell/drug therapy	angiogenesis inhibitors/therapeutic use	0.8301902991225216	0.0012219719371479	0	1	0.021505376344086	0.0026891839170452
carcinoma renal cell/drug therapy	myocarditis/chemically induced	0.8301902991225216	0.0012219719371479	0	1	0.021505376344086	0.0026891839170452
carcinoma renal cell/drug therapy	hepatitis autoimmune/etiology	0.8301902991225216	0.0012219719371479	0	1	0.021505376344086	0.0026891839170452
carcinoma renal cell/drug therapy	myasthenia gravis/chemically induced	0.8301902991225216	0.0012219719371479	0	1	0.021505376344086	0.0026891839170452
carcinoma renal cell/drug therapy	ipilimumab/therapeutic use	0.5846350039324011	3.414059531747782e-07	0	2	0.0007012622720897	2.1932746082743324e-06
diabetes mellitus type 1/chemically induced	exanthema/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
diabetes mellitus type 1/chemically induced	bevacizumab/administration & dosage	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
diabetes mellitus type 1/chemically induced	fatigue/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
diabetes mellitus type 1/chemically induced	pruritus/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
diabetes mellitus type 1/chemically induced	adrenal insufficiency/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
diabetes mellitus type 1/chemically induced	axitinib/administration & dosage	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
diabetes mellitus type 1/chemically induced	hypophysitis/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
diabetes mellitus type 1/chemically induced	angiogenesis inhibitors/therapeutic use	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
diabetes mellitus type 1/chemically induced	myocarditis/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
diabetes mellitus type 1/chemically induced	hepatitis autoimmune/etiology	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
diabetes mellitus type 1/chemically induced	myasthenia gravis/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
diabetes mellitus type 1/chemically induced	ipilimumab/therapeutic use	0.8301902991225216	0.0036027646835737	0	1	0.032258064516129	0.0067591691408641
exanthema/chemically induced	bevacizumab/administration & dosage	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
exanthema/chemically induced	fatigue/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
exanthema/chemically induced	pruritus/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
exanthema/chemically induced	adrenal insufficiency/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
exanthema/chemically induced	axitinib/administration & dosage	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
exanthema/chemically induced	hypophysitis/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
exanthema/chemically induced	angiogenesis inhibitors/therapeutic use	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
exanthema/chemically induced	myocarditis/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
exanthema/chemically induced	hepatitis autoimmune/etiology	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
exanthema/chemically induced	myasthenia gravis/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
exanthema/chemically induced	ipilimumab/therapeutic use	0.8301902991225216	0.0036027646835737	0	1	0.032258064516129	0.0067591691408641
bevacizumab/administration & dosage	fatigue/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
bevacizumab/administration & dosage	pruritus/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
bevacizumab/administration & dosage	adrenal insufficiency/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
bevacizumab/administration & dosage	axitinib/administration & dosage	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
bevacizumab/administration & dosage	hypophysitis/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
bevacizumab/administration & dosage	angiogenesis inhibitors/therapeutic use	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
bevacizumab/administration & dosage	myocarditis/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
bevacizumab/administration & dosage	hepatitis autoimmune/etiology	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
bevacizumab/administration & dosage	myasthenia gravis/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
bevacizumab/administration & dosage	ipilimumab/therapeutic use	0.8301902991225216	0.0036027646835737	0	1	0.032258064516129	0.0067591691408641
fatigue/chemically induced	pruritus/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
fatigue/chemically induced	adrenal insufficiency/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
fatigue/chemically induced	axitinib/administration & dosage	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
fatigue/chemically induced	hypophysitis/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
fatigue/chemically induced	angiogenesis inhibitors/therapeutic use	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
fatigue/chemically induced	myocarditis/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
fatigue/chemically induced	hepatitis autoimmune/etiology	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
fatigue/chemically induced	myasthenia gravis/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
fatigue/chemically induced	ipilimumab/therapeutic use	0.8301902991225216	0.0036027646835737	0	1	0.032258064516129	0.0067591691408641
pruritus/chemically induced	adrenal insufficiency/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
pruritus/chemically induced	axitinib/administration & dosage	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
pruritus/chemically induced	hypophysitis/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
pruritus/chemically induced	angiogenesis inhibitors/therapeutic use	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
pruritus/chemically induced	myocarditis/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
pruritus/chemically induced	hepatitis autoimmune/etiology	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
pruritus/chemically induced	myasthenia gravis/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
pruritus/chemically induced	ipilimumab/therapeutic use	0.8301902991225216	0.0036027646835737	0	1	0.032258064516129	0.0067591691408641
adrenal insufficiency/chemically induced	axitinib/administration & dosage	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
adrenal insufficiency/chemically induced	hypophysitis/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
adrenal insufficiency/chemically induced	angiogenesis inhibitors/therapeutic use	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
adrenal insufficiency/chemically induced	myocarditis/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
adrenal insufficiency/chemically induced	hepatitis autoimmune/etiology	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
adrenal insufficiency/chemically induced	myasthenia gravis/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
adrenal insufficiency/chemically induced	ipilimumab/therapeutic use	0.8301902991225216	0.0036027646835737	0	1	0.032258064516129	0.0067591691408641
axitinib/administration & dosage	hypophysitis/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
axitinib/administration & dosage	angiogenesis inhibitors/therapeutic use	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
axitinib/administration & dosage	myocarditis/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
axitinib/administration & dosage	hepatitis autoimmune/etiology	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
axitinib/administration & dosage	myasthenia gravis/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
axitinib/administration & dosage	ipilimumab/therapeutic use	0.8301902991225216	0.0036027646835737	0	1	0.032258064516129	0.0067591691408641
hypophysitis/chemically induced	angiogenesis inhibitors/therapeutic use	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
hypophysitis/chemically induced	myocarditis/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
hypophysitis/chemically induced	hepatitis autoimmune/etiology	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
hypophysitis/chemically induced	myasthenia gravis/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
hypophysitis/chemically induced	ipilimumab/therapeutic use	0.8301902991225216	0.0036027646835737	0	1	0.032258064516129	0.0067591691408641
angiogenesis inhibitors/therapeutic use	myocarditis/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
angiogenesis inhibitors/therapeutic use	hepatitis autoimmune/etiology	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
angiogenesis inhibitors/therapeutic use	myasthenia gravis/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
angiogenesis inhibitors/therapeutic use	ipilimumab/therapeutic use	0.8301902991225216	0.0036027646835737	0	1	0.032258064516129	0.0067591691408641
myocarditis/chemically induced	hepatitis autoimmune/etiology	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
myocarditis/chemically induced	myasthenia gravis/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
myocarditis/chemically induced	ipilimumab/therapeutic use	0.8301902991225216	0.0036027646835737	0	1	0.032258064516129	0.0067591691408641
hepatitis autoimmune/etiology	myasthenia gravis/chemically induced	0.8301902991225216	0.0002334339983105	0	1	0.010752688172043	0.0005814517869145
hepatitis autoimmune/etiology	ipilimumab/therapeutic use	0.8301902991225216	0.0036027646835737	0	1	0.032258064516129	0.0067591691408641
myasthenia gravis/chemically induced	ipilimumab/therapeutic use	0.8301902991225216	0.0036027646835737	0	1	0.032258064516129	0.0067591691408641
ipilimumab/therapeutic use	pneumonia/chemically induced	0.5846350039324011	2.193543423523181e-05	0	2	0.0020883744586409	8.238741834807539e-05
ipilimumab/therapeutic use	proton pump inhibitors/adverse effects	0.8301902991225216	1.4077731091965973e-08	0	1	0.032258064516129	9.948263304989288e-08
ipilimumab/therapeutic use	carcinoma non-small-cell lung/drug therapy	0.8301902991225216	7.1540639148715e-05	0	1	0.0638148667601683	0.0002585218551055
CD8A	colitis ulcerative/immunology	0.5846350039324011	0.0013552885133465	0	2	0.0023375409069658	0.0029452055620332
CD8A	cd8-positive t-lymphocytes/drug effects	0.5846350039324011	0.0013552885133465	0	2	0.0023375409069658	0.0029452055620332
CD8A	phenotype	0.5846350039324011	0.0013552885133465	0	2	0.0023375409069658	0.0029452055620332
CD8A	CD4	0.5846350039324011	0.0002095106790775	0	2	0.0023375409069658	0.0005814517869145
CD8A	CD68	0.5846350039324011	0.0002095106790775	0	2	0.0023375409069658	0.0005814517869145
colitis ulcerative/immunology	pyrimidines/therapeutic use	0.8301902991225216	0.0022342109308476	0	1	0.0427769985974754	0.0044825178297132
colitis ulcerative/immunology	piperidines/therapeutic use	0.8301902991225216	0.0022342109308476	0	1	0.0427769985974754	0.0044825178297132
colitis ulcerative/immunology	macrophages/drug effects	0.8301902991225216	1.095585194110793e-05	0	1	0.021505376344086	4.301186317620151e-05
colitis ulcerative/immunology	interferon-gamma/metabolism	0.8301902991225216	0.000124270133592	0	1	0.021505376344086	0.0003619960532727
colitis ulcerative/immunology	immunologic memory/drug effects	0.8301902991225216	0.000124270133592	0	1	0.021505376344086	0.0003619960532727
colitis ulcerative/immunology	crohn disease/immunology	0.8301902991225216	1.095585194110793e-05	0	1	0.021505376344086	4.301186317620151e-05
colitis ulcerative/immunology	graft vs host disease/immunology	0.8301902991225216	1.095585194110793e-05	0	1	0.021505376344086	4.301186317620151e-05
colitis ulcerative/immunology	cd8-positive t-lymphocytes/drug effects	0.5846350039324011	1.4021638738981324e-08	0	2	0.0002337540906965	9.948263304989288e-08
colitis ulcerative/immunology	phenotype	0.5846350039324011	1.4021638738981324e-08	0	2	0.0002337540906965	9.948263304989288e-08
colitis ulcerative/immunology	CD4	0.8301902991225216	0.0012219719371479	0	1	0.0427769985974754	0.0026891839170452
colitis ulcerative/immunology	CD68	0.8301902991225216	0.0012219719371479	0	1	0.0427769985974754	0.0026891839170452
cd8-positive t-lymphocytes/drug effects	pyrimidines/therapeutic use	0.8301902991225216	0.0022342109308476	0	1	0.0427769985974754	0.0044825178297132
cd8-positive t-lymphocytes/drug effects	piperidines/therapeutic use	0.8301902991225216	0.0022342109308476	0	1	0.0427769985974754	0.0044825178297132
cd8-positive t-lymphocytes/drug effects	macrophages/drug effects	0.8301902991225216	1.095585194110793e-05	0	1	0.021505376344086	4.301186317620151e-05
cd8-positive t-lymphocytes/drug effects	interferon-gamma/metabolism	0.8301902991225216	0.000124270133592	0	1	0.021505376344086	0.0003619960532727
cd8-positive t-lymphocytes/drug effects	immunologic memory/drug effects	0.8301902991225216	0.000124270133592	0	1	0.021505376344086	0.0003619960532727
cd8-positive t-lymphocytes/drug effects	crohn disease/immunology	0.8301902991225216	1.095585194110793e-05	0	1	0.021505376344086	4.301186317620151e-05
cd8-positive t-lymphocytes/drug effects	graft vs host disease/immunology	0.8301902991225216	1.095585194110793e-05	0	1	0.021505376344086	4.301186317620151e-05
cd8-positive t-lymphocytes/drug effects	phenotype	0.5846350039324011	1.4021638738981324e-08	0	2	0.0002337540906965	9.948263304989288e-08
cd8-positive t-lymphocytes/drug effects	CD4	0.8301902991225216	0.0012219719371479	0	1	0.0427769985974754	0.0026891839170452
cd8-positive t-lymphocytes/drug effects	CD68	0.8301902991225216	0.0012219719371479	0	1	0.0427769985974754	0.0026891839170452
phenotype	pyrimidines/therapeutic use	0.8301902991225216	0.0022342109308476	0	1	0.0427769985974754	0.0044825178297132
phenotype	piperidines/therapeutic use	0.8301902991225216	0.0022342109308476	0	1	0.0427769985974754	0.0044825178297132
phenotype	macrophages/drug effects	0.8301902991225216	1.095585194110793e-05	0	1	0.021505376344086	4.301186317620151e-05
phenotype	interferon-gamma/metabolism	0.8301902991225216	0.000124270133592	0	1	0.021505376344086	0.0003619960532727
phenotype	immunologic memory/drug effects	0.8301902991225216	0.000124270133592	0	1	0.021505376344086	0.0003619960532727
phenotype	crohn disease/immunology	0.8301902991225216	1.095585194110793e-05	0	1	0.021505376344086	4.301186317620151e-05
phenotype	graft vs host disease/immunology	0.8301902991225216	1.095585194110793e-05	0	1	0.021505376344086	4.301186317620151e-05
phenotype	CD4	0.8301902991225216	0.0012219719371479	0	1	0.0427769985974754	0.0026891839170452
phenotype	CD68	0.8301902991225216	0.0012219719371479	0	1	0.0427769985974754	0.0026891839170452
CD4	macrophages/drug effects	0.8301902991225216	6.083958906666354e-07	0	1	0.021505376344086	3.696876940738663e-06
CD4	crohn disease/immunology	0.8301902991225216	6.083958906666354e-07	0	1	0.021505376344086	3.696876940738663e-06
CD4	graft vs host disease/immunology	0.8301902991225216	6.083958906666354e-07	0	1	0.021505376344086	3.696876940738663e-06
CD4	CD68	0.5846350039324011	1.8818280267396406e-13	0	2	0.0002337540906965	2.992106562516028e-12
CD68	macrophages/drug effects	0.8301902991225216	6.083958906666354e-07	0	1	0.021505376344086	3.696876940738663e-06
CD68	crohn disease/immunology	0.8301902991225216	6.083958906666354e-07	0	1	0.021505376344086	3.696876940738663e-06
CD68	graft vs host disease/immunology	0.8301902991225216	6.083958906666354e-07	0	1	0.021505376344086	3.696876940738663e-06
pneumonia/chemically induced	carcinoma non-small-cell lung/drug therapy	0.8301902991225216	0.0002123977946096	0	1	0.0638148667601683	0.0005814517869145
pneumonia/chemically induced	dose-response relationship drug	0.8301902991225216	0.0019308727447	0	1	0.0638148667601683	0.0040050466235307
dose-response relationship drug	steroids/therapeutic use	0.8301902991225216	2.0925394750292978e-10	0	1	0.0427769985974754	2.181729682161694e-09
protein kinase inhibitors/therapeutic use	pyrimidines/therapeutic use	0.8301902991225216	1.4077731091965973e-08	0	1	0.021505376344086	9.948263304989288e-08
protein kinase inhibitors/therapeutic use	piperidines/therapeutic use	0.8301902991225216	1.4077731091965973e-08	0	1	0.021505376344086	9.948263304989288e-08
disease susceptibility	postoperative complications	0.8301902991225216	0.0	0	1	0.010752688172043	0.0
pyrimidines/therapeutic use	piperidines/therapeutic use	0.5846350039324011	4.544509213388892e-11	0	2	0.0002337540906965	4.983289413302303e-10
pyrimidines/therapeutic use	interferon-gamma/metabolism	0.8301902991225216	3.675433327188227e-05	0	1	0.021505376344086	0.0001340865542691
pyrimidines/therapeutic use	immunologic memory/drug effects	0.8301902991225216	3.675433327188227e-05	0	1	0.021505376344086	0.0001340865542691
piperidines/therapeutic use	immunologic memory/drug effects	0.8301902991225216	3.675433327188227e-05	0	1	0.021505376344086	0.0001340865542691
piperidines/therapeutic use	interferon-gamma/metabolism	0.8301902991225216	3.675433327188227e-05	0	1	0.021505376344086	0.0001340865542691
interferon-gamma/metabolism	immunologic memory/drug effects	0.8301902991225216	2.572653080568088e-07	0	1	0.010752688172043	1.663939687364038e-06
melanoma/genetics	receptors cxcr6/genetics	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
melanoma/genetics	gene expression regulation/genetics	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
melanoma/genetics	receptors cxcr3/genetics	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
melanoma/genetics	cd8-positive t-lymphocytes/cytology	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
melanoma/genetics	myeloid cells/cytology	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
melanoma/genetics	ctla-4 antigen/immunology	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
melanoma/genetics	colitis/drug therapy	0.8301902991225216	0.0004982368131516	0	1	0.032258064516129	0.0011838553418347
melanoma/genetics	receptors antigen t-cell/genetics	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
melanoma/genetics	t-lymphocytes regulatory/cytology	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
melanoma/genetics	chemokines/metabolism	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
melanoma/genetics	multigene family	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
receptors cxcr6/genetics	gene expression regulation/genetics	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
receptors cxcr6/genetics	receptors cxcr3/genetics	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
receptors cxcr6/genetics	cd8-positive t-lymphocytes/cytology	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
receptors cxcr6/genetics	myeloid cells/cytology	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
receptors cxcr6/genetics	ctla-4 antigen/immunology	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
receptors cxcr6/genetics	colitis/drug therapy	0.8301902991225216	0.0004982368131516	0	1	0.032258064516129	0.0011838553418347
receptors cxcr6/genetics	receptors antigen t-cell/genetics	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
receptors cxcr6/genetics	t-lymphocytes regulatory/cytology	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
receptors cxcr6/genetics	chemokines/metabolism	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
receptors cxcr6/genetics	multigene family	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
gene expression regulation/genetics	receptors cxcr3/genetics	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
gene expression regulation/genetics	cd8-positive t-lymphocytes/cytology	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
gene expression regulation/genetics	myeloid cells/cytology	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
gene expression regulation/genetics	ctla-4 antigen/immunology	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
gene expression regulation/genetics	colitis/drug therapy	0.8301902991225216	0.0004982368131516	0	1	0.032258064516129	0.0011838553418347
gene expression regulation/genetics	receptors antigen t-cell/genetics	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
gene expression regulation/genetics	t-lymphocytes regulatory/cytology	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
gene expression regulation/genetics	chemokines/metabolism	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
gene expression regulation/genetics	multigene family	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
receptors cxcr3/genetics	cd8-positive t-lymphocytes/cytology	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
receptors cxcr3/genetics	myeloid cells/cytology	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
receptors cxcr3/genetics	ctla-4 antigen/immunology	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
receptors cxcr3/genetics	colitis/drug therapy	0.8301902991225216	0.0004982368131516	0	1	0.032258064516129	0.0011838553418347
receptors cxcr3/genetics	receptors antigen t-cell/genetics	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
receptors cxcr3/genetics	t-lymphocytes regulatory/cytology	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
receptors cxcr3/genetics	chemokines/metabolism	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
receptors cxcr3/genetics	multigene family	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
cd8-positive t-lymphocytes/cytology	myeloid cells/cytology	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
cd8-positive t-lymphocytes/cytology	ctla-4 antigen/immunology	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
cd8-positive t-lymphocytes/cytology	colitis/drug therapy	0.8301902991225216	0.0004982368131516	0	1	0.032258064516129	0.0011838553418347
cd8-positive t-lymphocytes/cytology	receptors antigen t-cell/genetics	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
cd8-positive t-lymphocytes/cytology	t-lymphocytes regulatory/cytology	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
cd8-positive t-lymphocytes/cytology	chemokines/metabolism	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
cd8-positive t-lymphocytes/cytology	multigene family	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
myeloid cells/cytology	ctla-4 antigen/immunology	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
myeloid cells/cytology	colitis/drug therapy	0.8301902991225216	0.0004982368131516	0	1	0.032258064516129	0.0011838553418347
myeloid cells/cytology	receptors antigen t-cell/genetics	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
myeloid cells/cytology	t-lymphocytes regulatory/cytology	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
myeloid cells/cytology	chemokines/metabolism	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
myeloid cells/cytology	multigene family	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
ctla-4 antigen/immunology	colitis/drug therapy	0.8301902991225216	0.0004982368131516	0	1	0.032258064516129	0.0011838553418347
ctla-4 antigen/immunology	receptors antigen t-cell/genetics	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
ctla-4 antigen/immunology	t-lymphocytes regulatory/cytology	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
ctla-4 antigen/immunology	chemokines/metabolism	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
ctla-4 antigen/immunology	multigene family	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
colitis/drug therapy	receptors antigen t-cell/genetics	0.8301902991225216	0.0004982368131516	0	1	0.032258064516129	0.0011838553418347
colitis/drug therapy	t-lymphocytes regulatory/cytology	0.8301902991225216	0.0004982368131516	0	1	0.032258064516129	0.0011838553418347
colitis/drug therapy	chemokines/metabolism	0.8301902991225216	0.0004982368131516	0	1	0.032258064516129	0.0011838553418347
colitis/drug therapy	multigene family	0.8301902991225216	0.0004982368131516	0	1	0.032258064516129	0.0011838553418347
receptors antigen t-cell/genetics	t-lymphocytes regulatory/cytology	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
receptors antigen t-cell/genetics	chemokines/metabolism	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
receptors antigen t-cell/genetics	multigene family	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
t-lymphocytes regulatory/cytology	chemokines/metabolism	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
t-lymphocytes regulatory/cytology	multigene family	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
chemokines/metabolism	multigene family	0.8301902991225216	8.684265345948461e-06	0	1	0.010752688172043	3.540508179502065e-05
tryptophan/pharmacology	AHR	0.8301902991225216	0.0	0	1	0.010752688172043	0.0
intestinal mucosa/immunology	colon/immunology	0.8301902991225216	0.0	0	1	0.021505376344086	0.0
colon/immunology	t-lymphocyte subsets/immunology	0.8301902991225216	0.0	0	1	0.021505376344086	0.0
lymphocytes/drug effects	melanoma/complications	0.8301902991225216	2.841507864870252e-05	0	1	0.032258064516129	0.0001046640348681
lymphocytes/drug effects	vitamin d/administration & dosage	0.8301902991225216	9.983374127386924e-10	0	1	0.010752688172043	7.743202371973273e-09
lymphocytes/drug effects	neutrophils/drug effects	0.8301902991225216	9.983374127386924e-10	0	1	0.010752688172043	7.743202371973273e-09
lymphocytes/drug effects	antibodies monoclonal/adverse effects	0.8301902991225216	9.983374127386924e-10	0	1	0.010752688172043	7.743202371973273e-09
vitamin d/administration & dosage	melanoma/complications	0.8301902991225216	2.841507864870252e-05	0	1	0.032258064516129	0.0001046640348681
vitamin d/administration & dosage	neutrophils/drug effects	0.8301902991225216	9.983374127386924e-10	0	1	0.010752688172043	7.743202371973273e-09
vitamin d/administration & dosage	antibodies monoclonal/adverse effects	0.8301902991225216	9.983374127386924e-10	0	1	0.010752688172043	7.743202371973273e-09
neutrophils/drug effects	melanoma/complications	0.8301902991225216	2.841507864870252e-05	0	1	0.032258064516129	0.0001046640348681
neutrophils/drug effects	antibodies monoclonal/adverse effects	0.8301902991225216	9.983374127386924e-10	0	1	0.010752688172043	7.743202371973273e-09
antibodies monoclonal/adverse effects	melanoma/complications	0.8301902991225216	2.841507864870252e-05	0	1	0.032258064516129	0.0001046640348681
macrophages/drug effects	crohn disease/immunology	0.8301902991225216	1.6913137557139635e-11	0	1	0.010752688172043	1.9094832224273623e-10
macrophages/drug effects	graft vs host disease/immunology	0.8301902991225216	1.6913137557139635e-11	0	1	0.010752688172043	1.9094832224273623e-10
crohn disease/immunology	graft vs host disease/immunology	0.8301902991225216	1.6913137557139635e-11	0	1	0.010752688172043	1.9094832224273623e-10
colitis ulcerative/physiopathology	crohn disease/physiopathology	0.8301902991225216	0.0	0	1	0.010752688172043	0.0
melanoma/complications	colitis collagenous/drug therapy	0.8301902991225216	2.204902926905561e-12	0	1	0.032258064516129	3.2361190650275463e-11
melanoma/complications	skin neoplasms/complications	0.8301902991225216	2.204902926905561e-12	0	1	0.032258064516129	3.2361190650275463e-11
colitis collagenous/drug therapy	skin neoplasms/complications	0.8301902991225216	0.0	0	1	0.010752688172043	0.0
ustekinumab/therapeutic use	colitis ulcerative/drug therapy	0.8301902991225216	0.0	0	1	0.021505376344086	0.0
ustekinumab/therapeutic use	interleukin-23/antagonists & inhibitors	0.8301902991225216	0.0	0	1	0.010752688172043	0.0
ustekinumab/therapeutic use	interleukin-12/antagonists & inhibitors	0.8301902991225216	0.0	0	1	0.010752688172043	0.0
colitis ulcerative/drug therapy	interleukin-23/antagonists & inhibitors	0.8301902991225216	0.0	0	1	0.021505376344086	0.0
colitis ulcerative/drug therapy	interleukin-12/antagonists & inhibitors	0.8301902991225216	0.0	0	1	0.021505376344086	0.0
interleukin-23/antagonists & inhibitors	interleukin-12/antagonists & inhibitors	0.8301902991225216	0.0	0	1	0.010752688172043	0.0
glycoproteins/metabolism	biomarkers/metabolism	0.8301902991225216	0.0	0	1	0.010752688172043	0.0
glycoproteins/metabolism	adenocarcinoma of lung/drug therapy	0.8301902991225216	0.0	0	1	0.010752688172043	0.0
biomarkers/metabolism	adenocarcinoma of lung/drug therapy	0.8301902991225216	0.0	0	1	0.010752688172043	0.0
